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Abstract		 Chronic	 Lymphocytic	 Leukemia	 (CLL)	 is	 characterized	 by	 the	accumulation	 of	 mature	 clonal	 CD19+/CD5+/CD23+	 B	 lymphocytes	 in	peripheral	 blood,	 bone	marrow,	 and	 lymphoid	 tissues.	Despite	 their	 in	vivo	prolonged	 lifespan	 due	 to	 intrinsic	 defects,	 CLL	 leukemic	 cells	 rapidly	undergo	 spontaneous	 apoptosis	 in	 vitro,	 highlighting	 the	 need	 of	 extrinsic	signals	delivered	by	the	microenvironment.		Several	molecules,	 including	those	released	by	mesenchymal	stromal	cells	 (MSCs),	 signal	 through	 JAK	 (Janus	 kinases)-STAT	 (signal	 transducers	and	 activators	 of	 transcription)	 pathways.	 During	 the	 PhD	 course,	 we	particularly	 focused	 on	 JAK2/STAT3	 axis	 since	 IL-6,	 one	 of	 the	 most	abundant	cytokines	released	in	the	CLL	microenvironment,	is	the	key	ligand	of	the	receptor	triggering	this	pathway.	The	deregulation	of	JAK2/STAT3	axis	may	 lead	 to	 aberrant	 activation	 of	 STAT3	 and,	 as	 a	 result,	 to	 tumor	development	in	hematopoietic	cells.	By	 western	 blotting,	 flow	 cytometry	 analysis,	 subcellular	fractionation,	and	confocal	microscopy,	we	analyzed	76	CLL	patients	and	23	healthy	donors	to	investigate	STAT3	involvement	in	CLL	cell	survival.	We	demonstrated	 that	 STAT3	 expression	was	 higher	 in	malignant	B	cells	 (MFI:	 CLL	 cells	 1.28±0.13	 vs	 normals	 0.61±0.09,	 Student’s	 t	 test,	p<0.001)	and	the	protein	is	significantly	phosphorylated	at	Tyr705	compared	with	the	normal	counterpart	(B	lymphocytes	from	healthy	donors)	(MFI:	CLL	cells	 211.3±35.85	 vs	 normals	 46.50±6.12,	 Student’s	 t	 test,	 p<0.05),	 thus	showing	its	constitutive	activation	in	CLL.	Afterwards,	we	pointed	out	that	the	 in	vitro	 incubation	of	 leukemic	B	cells	 with	 AG490	 and	 Stattic,	 specific	 inhibitors	 of	 JAK2	 and	 STAT3,	respectively,	 induce	 a	 dose-dependent	 apoptosis	 of	 CLL	 B	 cells	 (e.g.	 Cell	viability,	 24h:	 CLL	 cells	 alone	 62.90±4.24%	 vs	 CLL	 cells	 +	 AG490	 50µM	38.30±7.22%,	 Student’s	 t	 test,	 p<0.01;	 CLL	 cells	 alone	 60.96±3.91%	 vs	CLL	cells	 +	 Stattic	 10µM	31.78±4.31%,	 Student’s	 t	 test,	 p<0.0001).	 Both	 AG490	and	 Stattic	 were	 able	 to	 bypass	 the	 microenvironmental	 protection	 when	
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neoplastic	 B	 cells	 were	 co-cultured	with	MSCs	 (e.g.	 Cell	 viability,	 48h:	 CLL	cells	66.80±6.28%	vs	CLL	cells	+	AG490	100µM	22.50±7.50%,	Student’s	t	test,	p<0.01;	 CLL	 cells	 57.51±4.95%	 vs	CLL	 cells	 +	 Stattic	 10µM	 26.25±5.45%,	Student’s	t	test,	p<0.001).	In	 addition	 to	 JAK2/STAT3	 inhibition,	 we	 showed	 that	 AG490	treatment	 on	 CLL	 cells	 can	 mediate	 other	 effects:	 i)	 it	 activates	 SHP-1,	decreasing	 its	 phosphorylation	 at	 Ser591;	 ii)	 it	 inactivates	 protein	 Lyn,	reducing	the	phosphorylation	 in	 its	active	site	at	Tyr396.	Lyn,	a	Tyr-kinase,	and	SHP-1,	a	Tyr-phosphatase,	are	both	involved	in	the	prolonged	lifespan	of	neoplastic	CLL	cells.	In	 conclusion,	 the	 ability	 of	 AG490	 and	 Stattic	 to	 induce	 apoptosis	 in	leukemic	B	 cells,	 bypassing	 the	 pro-survival	 stimuli	 provided	by	 the	 tumor	microenvironment,	 represents	 a	 starting	 point	 for	 the	 development	 of	 new	therapeutic	strategies	in	CLL,	providing	at	the	same	time	new	insights	on	the	cross-talk	between	JAK/STAT	and	BCR/Lyn	axes	in	CLL	cells.																			
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Riassunto		 	La	Leucemia	Linfatica	Cronica	(LLC)	è	un	disordine	linfoproliferativo	caratterizzato	 dall’accumulo	 di	 linfociti	 B	 maturi,	 con	 immunofenotipo	CD19+/CD5+/CD23+,	nel	sangue	periferico,	 in	quello	midollare	e	nei	tessuti	linfoidi.	 Nonostante	 le	 cellule	 leucemiche	 in	 vivo	 non	 vadano	 incontro	 ad	apoptosi,	 se	 poste	 in	 vitro	 muoiono	 rapidamente;	 questo	 evidenzia	l’importanza	del	microambiente	nella	sopravvivenza	del	clone	neoplastico.		Diverse	molecole,	 incluse	quelle	 rilasciate	dalle	 cellule	mesenchimali	stromali	 (MSC)	 agiscono	 tramite	 la	 via	 di	 JAK	 (Janus	Kinase)/STAT	 (Signal	
Transducer	and	Activators	of	Transcription).	Nel	 corso	 del	 dottorato,	 ci	 siamo	 concentrati	 in	 particolare	 sull’asse	JAK2/STAT3	 in	 quanto	 IL-6,	 una	 delle	 citochine	 più	 abbondanti	 tra	 quelle	presenti	nel	microambiente,	è	 il	 ligando	principale	del	 recettore	a	monte	di	questa	 via.	 La	 deregolazione	 dell’asse	 JAK2/STAT3	 può	 portare	all’attivazione	 incontrollata	di	 STAT3	e,	 conseguentemente,	 allo	 sviluppo	di	tumori	delle	cellule	ematopoietiche	Tramite	 western	 blotting,	 citometria	 a	 flusso,	 frazionamento	subcellulare	e	microscopia	confocale,	abbiamo	analizzato	76	pazienti	con	LLC	e	 23	 donatori	 sani	 al	 fine	 di	 studiare	 il	 coinvolgimento	 di	 STAT3	 nella	sopravvivenza	della	cellula	leucemica.	Abbiamo	dimostrato	come	 l’espressione	di	STAT3	sia	maggiore	nelle	cellule	 neoplastiche	 (MFI:	 cellule	 di	 LLC	 1.28±0.13	 vs	 normali	 0.61±0.09,	Student’s	 t	 test,	 p<0.001)	 e	 come	 sia	 significativamente	 fosforilata	 alla	Tyr705	 in	 confronto	 ai	 linfociti	 B	 di	 donatori	 sani	 (MFI:	 cellule	 di	 LLC	211.3±35.85	 vs	normali	 46.50±6.12,	 Student’s	 t	 test,	 p<0.05),	 evidenziando	così	la	sua	attivazione	costitutiva	nella	CLL.	Dopo	di	ciò,	abbiamo	osservato	come	il	trattamento	 in	vitro	di	cellule	leucemiche	con	AG490	e	Stattic,	rispettivamente	 inibitori	specifici	di	 JAK2	e	di	STAT3,	induca	apoptosi	dose-dipendente	nelle	cellule	B	di	LLC	(es.	Vitalità	cellulare,	 24h:	 cellule	di	 LLC	62.90±4.24%	vs	 cellule	di	 LLC	+	AG490	50µM	38.30±7.22%,	Student’s	t	 test,	p<0.01;	cellule	di	LLC	60.96±3.91%	vs	cellule	
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di	LLC	+	Stattic	10µM	31.78±4.31%,	Student’s	t	test,	p<0.0001).		Sia	 AG490	 che	 Stattic	 si	 sono	 dimostrati	 capaci	 di	 superare	 la	protezione	 fornita	 dal	 microambiente	 quando	 le	 cellule	 neoplastiche	 sono	poste	 in	 cultura	 insieme	 alle	MSC	 (es.	 Vitalità	 cellulare,	 48h:	 cellule	 di	 LLC	66.80±6.28%	vs	cellule	di	LLC	+	AG490	100µM	22.50±7.50%,	Student’s	t	test,	p<0.01;	 cellule	 di	 LLC	 57.51±4.95%	 vs	 cellule	 di	 LLC	 +	 Stattic	 10µM	26.25±5.45%,	Student’s	t	test,	p<0.001).	Abbiamo	 dimostrato	 come	 AG490	 non	 sia	 solo	 in	 grado	 di	 inibire	l’asse	JAK2/STAT3,	ma	possa	anche	mediare	altri	effetti	come:	i)	l’attivazione	di	 SHP-1	 diminuendo	 la	 sua	 fosforilazione	 in	 Ser591;	 ii)	 l’inibizione	 della	proteina	Lyn,	riducendo	la	fosforilazione	del	sito	attivo	in	Tyr396.		Lyn,	 una	 tirosin-chinasi,	 e	 SHP-1,	 una	 tirosin-fosfatasi,	 sono	 coinvolte	 nella	sopravvivenza	delle	cellule	di	LLC.	In	conclusione,	la	capacità	di	AG490	e	Stattic	di	indurre	apoptosi	nelle	cellule	 B	 leucemiche	 superando	 la	 protezione	 fornita	 dal	 microambiente,	rappresenta	 un	 punto	 di	 partenza	 per	 lo	 sviluppo	 di	 nuove	 strategie	terapeutiche	nella	LLC,	fornendo	allo	stesso	tempo	nuove	informazioni	per	la	caratterizzazione	del	crosstalk	 tra	 l’asse	 JAK2/STAT3	e	 il	pathway	BCR/Lyn	nelle	cellule	leucemiche.				 	
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INTRODUCTION			
1.	Chronic	Lymphocytic	Leukemia	(CLL)	
	
1.1	Epidemiology	and	etiology			 B	 cell	 Chronic	Lymphocytic	 Leukemia	 (CLL)	 is	 a	 lymphoproliferative	disorder	characterized	by	the	accumulation	of	long-lived	monoclonal	B	cells	in	 peripheral	 blood,	 bone	marrow	 and	 lymphoid	 tissues.	 CLL	 lymphocytes	show	 a	 CD19+/CD5+/CD23+	 membrane	 phenotype	 and	 are	 blocked	 in	G0/G1	phase	of	the	cell	cycle1.	CLL	is	the	most	common	adult	leukemia	in	the	Western	world	and	is	more	prevalent	in	men	than	in	women	with	a	male	to	female	ratio	of	1.5-2:1.	The	incidence	rates	between	men	and	women	are	5.6	(in	 men)	 and	 4.3	 (in	 women)	 cases	 per	 100,000	 inhabitants	 per	 year,	respectively.	 In	 Europe,	 these	 incidence	 rates	 are	 5.87	 and	 4.01	 cases	 per	100,000	population	per	year,	respectively.	CLL	 is	considered	to	be	mainly	a	disease	of	the	elderly,	with	a	mean	age	at	diagnosis	of	70	years;	however,	it	is	not	unusual	 to	diagnose	 it	 in	younger	 individuals	 from	30	years	of	age.	The	incidence	increases	rapidly	with	increasing	age2,3	(Figure	1).		
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Figure 1. Incidence of CLL Age-specific incidence of CLL (adapted from Redaelli et al)3. 
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The	 etiology	 is	 still	 unknown;	 the	 exposure	 to	 common	 carcinogens	does	not	 seem	 to	 be	 associated	with	 the	disease	progression.	More	 studies	are	in	progress	to	assess	a	potential	relation	among	CLL	onset,	inflammation,	and	 autoimmune	 conditions4,5.	 A	 familiarity	 of	 this	 pathology	 is	 well	documented	 in	 the	 8-10%	 of	 cases.	 Moreover,	 it	 has	 been	 highlighted	 the	phenomenon	of	the	anticipation	in	which	inherited	disease	is	diagnosed	at	an	earlier	age	and	in	a	more	aggressive	form	in	the	later	generations	of	a	family6.		
1.2	Clinical	features			 The	clinical	course	of	 this	disorder	 is	highly	variable,	 ranging	 from	a	stable	 to	 a	 progressive	 and	 severe	 disease7:	 some	 patients	 remain	asymptomatic	 without	 any	 treatment,	 while	 others	 present	 an	 aggressive	outcome	 that	 is	 difficult	 to	 control	 with	 chemotherapy.	 About	 70%	 of	patients	 are	 asymptomatic	 at	 diagnosis	 and	 it	 is	 carried	 out	 after	 detailed	examinations	 followed	 the	 finding	 of	 lymphocytosis	 at	 examination	 blood	count;	in	other	cases,	the	pathology	occurs	with	asthenia,	weight	loss,	fever,	lymphadenopathy,	 splenomegaly,	 and	 hepatomegaly.	 Some	 patients	 could	show	autoimmune	phenomenons,	such	as	hemolytic	anemia	(11%	of	cases)	or	 autoimmune	 thrombocytopenia	 (2%	 cases)	 that	 are	 typically	 present	 in	advanced	 and	 multi-treated	 disease.	 The	 typical	 CLL	hypogammaglobulinemia	could	induce	immunodeficiency	and	high	mortality	for	infections8,9.	 		 Although	 the	 causes	 of	 death	 are	 often	 attributed	 to	 the	 underlying	disease,	 in	 some	cases	progressing	 syndromes	with	a	poor	prognosis	 could	occur:	 one	 of	 these	 is	 the	 Richter's	 syndrome	 in	which	 CLL	 changes	 into	 a	fast-growing	diffuse	large	B	cell	lymphoma.	Another	evolution	could	be	the	B	cell	 prolymphocytic	 leukemia	 (B-PLL)	 that	 is	 more	 aggressive	 and	characterized	 by	 malignant	 B	 cells	 larger	 than	 average.	 The	 occurrence	 of	acute	 lymphoblastic	 leukemia	 is	 very	 rare,	 while	 acute	 myeloid	 leukemia,	such	 as	 non-hematological	 disease,	 could	 be	 correlated	 with	 CLL	immunological	deficit	and	chemotherapy10.	
	 13	
1.3	Diagnosis			 It	 is	crucial	to	verify	that	the	patient	 is	really	suffering	from	CLL	and	not	 by	 another	 lymphoproliferative	 disease	 that	 can	masquerade	 as	 a	 CLL,	such	 as	 hairy	 cell	 leukemia,	 or	 leukemic	 manifestations	 of	 mantle	 cell	lymphoma,	marginal	zone	lymphoma,	splenic	marginal	zone	lymphoma	with	circulating	villous	lymphocytes,	or	follicular	lymphoma.	To	achieve	this,	it	is	essential	 to	 evaluate	 the	 blood	 count,	 blood	 smear,	 and	 the	 immune	phenotype	 of	 the	 circulating	 lymphoid	 cells.	 The	 National	 Cancer	 Institute	diagnostic	criteria	include11:		 1. the	 presence	 of	 at	 least	 5x109	 B	 lymphocytes/L	 (5000/µL)	 in	 the	peripheral	 blood.	 Leukemic	 cells	 found	 in	 the	 blood	 smear	 are	characteristically	small	(7-10μm	diameter),	mature	lymphocytes	with	a	narrow	border	of	cytoplasm	and	a	dense	nucleus,	lacking	discernible	nucleoli,	 with	 partially	 aggregated	 chromatin.	 These	 cells	 may	 be	found	 mixed	 with	 larger	 or	 atypical	 cells,	 broken	 cells,	 or	prolymphocytes,	 which	 may	 comprise	 up	 to	 55%	 of	 the	 blood	lymphocytes.	 Typically,	 the	 "shadows	 of	 Gumprecht",	 that	 is	degenerated	cells	that	are	broken	in	slide	preparation,	are	present	in	the	peripheral	blood	smear	(Figure	2).		
2. Bone	marrow	lymphocytic	infiltration	exceeding	30%	of	the	nucleated	cells	(Figure	3).	Although	the	type	of	bone	marrow	infiltration	(diffuse	vs	 not	 diffuse)	 reflects	 the	 size	 of	 the	 tumor	 and	 provides	 feedback	
Figure 2. Peripheral (A) and Stromal (B) blood smear of a CLL patient. Arrows indicate Gumprecht 
shadows typical of CLL. 
B A 
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about	 the	 prognosis.	 Recent	 studies	 have	 shown	 that	 the	 prognostic	value	 of	 bone	 marrow	 biopsy	 (BOM)	 can	 be	 replaced	 by	 new	prognostic	factors.	Bone	marrow	aspirate	and	BOM	are	generally	not	required	 for	 the	 diagnosis	 of	 CLL;	 however,	 they	 can	 help	 in	 the	management	of	the	patient	to	discriminate	cytopenias	related	to	bone	marrow	infiltration	than	other	types;	
	 3. immunophenotype	analysis.	CLL	phenotype	is	characterized	by	three	elements:		a)	 the	expression	of	a	unique	type	of	immunoglobulin	light	chains	(κ	or	λ);	b)	 the	 co-expression	 of	 the	 T-cell	 antigen	 CD5	 and	 the	 B-cell	surface	antigens	CD19,	CD20,	and	CD23;	CD23	 is	of	particular	importance	 in	 the	 differential	 diagnosis	 with	 mantle	 cell	lymphoma	(CD5+	but	CD23-);	c)	 low	 levels	 of	 CD79b	 and	 surface	 immunoglobulin	 (sIg)	 that	 in	 CLL	appear	to	be	mainly	IgM	followed	by	IgD,	IgG,	and	IgA;	it	is	not	unusual	to	find	an	IgM	and	IgD	co-expression	(Figure	4).					
Figure 3. Marrow biopsy of a CLL patient. Preparation stained with hematoxylin-eosin (HE) and three 
immunohistological pictures that show some diagnostic markers. 
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	 										 In	CLL,	T	lymphocytes,	in	particular	CD8+	T	cells,	are	often	increased,	with	a	reduced	CD4/CD8	ratio.	They	show	activation	markers	such	as	CD25	and	 HLA-DR.	 Natural-Killer	 (NK)	 cells	 (CD16+/CD56+)	 are	 present	 in	 high	levels.	 Several	 analyses	 are	 performed	 to	 confirm	 the	 diagnosis	 and	 to	prevent	 complications:	 serum	 protein	 electrophoresis,	 Ig	 dosage,	 Coombs'	test,	 and	 analysis	 of	 renal	 and	 liver	 function.	 Before	 starting	 an	immunotherapy,	it	is	important	to	assess	the	absence	of	viral	infection,	such	as	Hepatitis	B	virus	(HBV),	Hepatitis	C	virus	(HCV),	Cytomegalovirus	(CMV),	Epstein-Barr	virus	(EBV),	Human	Immunodeficiency	virus	(HIV)12.			
Figure	4.	Cytograms	of	a	representative	case	of	CLL.		B	lymphocytes	analyzed	(CD19+)	are	positive	to	CD5	(A)	and	to	CD23	(B),	surface	IgM	(sIgM),	low	density	(C)	express	one	type	of	immunoglobuline	light	chain	(λ,	D).	
A	 C	
B	 D	
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1.4	Prognosis			 Since	 it	 is	difficult	 to	predict	 the	course	of	 the	disease	at	 the	 time	of	diagnosis	 and	 the	 value	 of	 an	 early	 treatment	 is	 uncertain,	 therapy	 is	currently	 recommended	 only	 for	 patients	 with	 a	 disease	 progressive,	symptomatic,	or	both13.	During	the	years,	different	parameters	or	prognostic	factors	were	proposed	to	define	the	clinical	course	of	CLL	patients.				
1.4.1	Clinical	prognostic	factors		 1. Clinical	 staging:	 There	 are	 two	widely	 accepted	 staging	methods	 in	both	patient	care	and	clinical	trials:	the	Rai	and	the	Binet	system.	The	original	 Rai	 classification	 was	 modified	 to	 reduce	 the	 number	 of	prognostic	 groups	 from	 5	 to	 3.	 Both	 systems	 now	 describe	 3	major	subgroups	with	 different	 clinical	 outcomes.	 These	 2	 staging	 systems	are	simple,	inexpensive,	and	can	be	applied	by	physicians	worldwide.	Both	 rely	 exclusively	 on	 physical	 examination	 and	 standard	laboratory	 tests	 and	 do	 not	 require	 ultrasound,	 computed	tomography,	or	magnetic	resonance	imaging11.			 	 The	Rai	system	is	so	developed:	
• low-risk	disease	(stage	0):	absolute	lymphocytosis	>15,000/µl	and	marrow	lymphocytosis	>40%;	
• intermediate-risk	 disease	 (stage	 I	 or	 II):	 lymphocytosis,	 enlarged	nodes	in	any	site,	and	splenomegaly	and/or	hepatomegaly	(lymph	nodes	being	palpable	or	not);	
• high-risk	 disease	 (stage	 III	 or	 IV):	 disease-related	 anemia	(Hb<110g/L)	or	thrombocytopenia	(as	defined	by	a	platelet	count	<100x109/L).		The	Binet	system	is	based	on	the	number	of	involved	areas,	as	defined	by	the	presence	of	lymph	nodes	with	a	diameter	greater	than	1	 cm	 or	 organomegaly,	 and	 the	 presence	 of	 anemia	 or	thrombocytopenia.	It	is	subdivided	into:	
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• stage	A.	Hb≥100g/L	 (10g/dL),	 platelets	 ≥100x109/L,	 and	up	 to	 2	lymph	node	areas	involved;	
• stage	B.	Hb≥100g/L,	platelets	≥100x109/L,	and	lymphoadenopathy	greater	than	that	defined	for	stage	A	(i.e.,	3	or	more	areas	of	nodal	or	organ	enlargement);	
• stage	C.	All	patients	who	have	Hb	<100g/L	and/or	a	platelet	count	<100x109/L,	irrespective	of	lymphoadenopathy.	2. Lymphocyte	 doubling	 time:	 it	 is	 less	 than	 12	 months	 and	 it	 is	associated	with	a	worse	clinical	course.	3. Bone	 marrow	 infiltration:	 a	 diffuse	 infiltration	 pattern	 correlates	with	a	bad	prognosis14.		
1.4.2	Biological	prognostic	factors			 The	 less	 recent	 biological	 prognostic	 factors	 are	 correlated	with	 the	expansion	of	the	leukemic	clone;	they	thus	become	indicative	only	when	the	disease	 is	 worsening.	 Their	 utility	 is	 limited	 because	 it	 is	 not	 possible	 to	program	the	therapeutic	strategy	basing	on	the	progression	risk	of	patients.	The	biological	prognostic	factors	comprehend:		 1. Prolymphocyte	 (PL)	percentage:	 if	 it	 is	 less	 than	 or	 equal	 to	 10%	(typical	CLL)	 the	probability	of	PL	 leukemia	evolution	 is	very	 low;	 if	the	percentage	is	between	11%	and	55%	there	is	an	intermediate	risk	of	CLL/PL	leukemia,	and	if	 it	 is	greater	than	55%	the	transformation	in	PL	leukemia	may	occur15.	2. β2	 microglobulin:	 this	 parameter	 is	 inversely	 correlated	 with	 the	survival.	 It	 is	 related	with	 the	 lymphocyte	 doubling	 time	 so	 that	 an	increase	 in	 β2	 microglobulin	 indicates	 an	 high	 neoplastic	 cell	proliferation15.		3. Thymidine	kinase	(TK)	level:	it	has	been	shown	that	elevated	serum	thymidine	 kinase	 (s-TK)	 levels	 predict	 disease	 progression	 in	 CLL.	Patients	 with	 s-TK	 values	 greater	 than	 7.1U/L	 have	 a	 median	
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progression	free	survival	(PFS)	of	8	months,	whereas	patients	with	s-TK	values	≤7.1U/L	expect	a	much	longer	PFS16.		4. Soluble	CD23	value:	serum	CD23	level	provides	significant	additional	prognostic	 information	 in	 terms	 of	 overall	 survival	 (OS)	 in	 CLL.	Among	 early	 stage	 patients,	 sCD23	 determination,	 at	 diagnosis	 and	during	the	course	of	the	disease,	may	help	to	the	early	identification	of	patients	who	will	rapidly	progress	to	upper	stages.	Functions	ascribed	to	sCD23	include	prevention	of	germinal	center	(GC)	B	cells	from	their	apoptosis,	proliferation	of	myeloid	precursor	cells,	and,	more	recently,	costimulation	 of	 interferon-γ	 (IFN-γ)	 production	 by	 T	 cells	 and	triggering	of	monokine	release	by	monocytes17.				 The	progressive	discoveries	on	CLL	pathogenesis	have	identified	new	prognostic	 markers	 that	 can	 better	 determine	 the	 clinical	 course.	 They	describe	 biological	 characteristic	 of	 leukemic	 clone	 that	 are	 crucial	 to	evaluate	its	proliferation	and	invasion	capability.	The	study	of	these	markers	is	 performed	 by	 flow	 cytometry,	 cytogenetic	 and	 molecular	 biology	techniques.	The	main	markers	are:		 1. Somatic	 Hypermutations	 (SHM)	 of	 the	 Ig	 heavy	 chain	 variable	region	 (VH)	 genes.	 Based	 on	 the	 numbers	 of	 somatic	 mutations	detected	 in	 these	 genes,	 the	 cases	 were	 divided	 into	 2	 categories:	"unmutated"	 (SHM-)	 or	 "mutated"	 (SHM+)	 (Figure	 5-6).	Conventionally,	patients	with	<2%	differences	 from	the	most	 similar	germline	 gene	 in	 both	 the	 expressed	 VH	 and	 VL	 genes	 were	 define	unmutated;	 mutated	 cases	 were	 defined	 as	 those	 in	 which	 the	 CLL	cells	 displayed	 ≥2%	 differences	 in	 either	 the	 expressed	 VH	 or	 VL	gene18,19.	 In	addition,	 the	stereotyped	VH3.21	gene	 is	an	unfavorable	prognostic	 marker	 independent	 of	 the	 IgVH	 mutational	 status.	However,	this	result	has	been	highlighted	especially	in	patients	living	in	 Northern	 Europe,	 while	 it	 was	 not	 confirmed	 in	 Mediterranean	countries11.			
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	 2. CD38	expression.	CD38	is	a	transmembrane	glycoprotein	expressed	on	the	surface	of	cells	in	a	significant	percentage	of	patients	with	CLL.	A	 previous	 study	 suggested	 that	 CD38	 expression	 has	 prognostic	value	 in	CLL	 (Figure	7).	Cases	with	CD38+	B	cells	>30%	show	a	bad	prognosis.	 Indeed,	 the	 cut-off	 to	discriminate	CD38+	 to	CD38-	 is	not	
Figure	5.	Hypothesis	on	origins	and	features	of	the	2	subsets	of	chronic	lymphocytic	leukemia.	The	development	of	unmutated	CLL	(U-CLL)	 is	 likely	to	be	from	a	naive	B	cell	 that	has	encountered	antigen	but	 with	 insufficient	 stimulus	 to	 form	 a	 germinal	 center	 (GC).	 This	 subset	 has	 a	 poorer	 prognosis.	 In	contrast,	mutated	 CLL	 (M-CLL)	 develops	 from	 a	 cell	 that,	 following	 antigen	 encounter,	 has	 undergone	somatic	mutation	and	presumably	antigen	selection	in	the	GC.	The	final	neoplastic	event	is	likely	to	have	occurred	after	exit	from	the	GC.	This	subset	has	a	better	prognosis.	(Adapted	from	Stevenson	et	al.19)	
Figure	6.	Time	 to	Treatment	and	Overall	 Survival	 in	 relationship	with	 IGHV	prognostic	marker.	The	median	time	to	treatment	and	Overall	Survival	 for	mutated	(M-IGHV)	and	unmutated	U-IGHV)	CLL	patients	
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unanimously	 defined:	 some	 authors	 place	 it	 at	 20%20	 or	 to	 7%21	 of	CD38+	B	cells.	CD38	has	an	independent	prognostic	value.	Moreover,	variability	 is	 the	 limit	 of	 this	 marker,	 in	 particular	 after	 treatment:	chemotherapy	affects	mainly	CD38-	cells,	determining	an	 increase	of	CD38+	cells	in	a	second	time18.			
	 3. Intracytoplasmatic	 expression	 of	 protein	 kinase	 associated	 to	
TCR	 ζ	 chain	 of	 70kDa	 (ZAP-70).	 Zeta-associated	 protein	 of	 70kDa	(ZAP-70)	 is	 a	 cytoplasmic	 tyrosine	 kinase	 which	 is	 a	 key	 signaling	molecule	 for	 T	 lymphocytes	 and	 NK	 cells.	 ZAP-70	 expression	 may	reflect	 an	 activation	 state	 of	 the	 malignant	 clone	 associated	 with	progressive	disease	or	may	be	involved	in	CLL	progression	because	of	its	function	as	a	tyrosine	kinase	that	can	signal	downstream	of	many	surface	receptors.	The	expression	of	ZAP-70	may	change	over	time	in	CLL,	 in	particular	during	clinical	progression,	 suggesting	 the	 interest	in	the	evaluation	of	ZAP-70	during	the	evolution	of	the	disease	(Figure	8)22.	 ZAP-70	 expression	 analysis	 can	 be	 performed	 with	 different	methods:	 flow	 cytometry,	 immunohistochemistry,	 western	 blotting,	and	 Real-Time	 PCR.	 Among	 these,	 flow	 cytometry	 is	 the	 most	advantageous	 for	 its	 diffusion	 and	 easiness	 of	 application.	 Anyhow	interlaboratory	variation	is	large	and	there	is	neither	a	consensus	nor	a	regulatory	approved	methodology23.		
Figure	7.	Time	 to	Treatment	and	Overall	 Survival	 in	 relationship	with	CD38	prognostic	marker.	The	 median	 time	 to	 treatment	 and	 Overall	 Survival	 for	 patients	 with	 a	 high	 (CD38+)	 or	 low	 (CD38-)	number	of	cell		expressing	this	transmembrane	glycoprotein.				
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	 4. Chromosomal	 alterations.	 CLL	 is	 also	 characterized	 by	 a	 genomic	instability	 that	 gives	 rise	 to	 several	 chromosomal	 aberrations,	 11q,	13q,	 17p	 deletions	 and	 12	 trisomy	 being	 the	 most	 relevant.	 Clonal	genomic	 aberrations	 can	 be	 identified	 in	 approximately	 80%	of	 CLL	patients	by	 fluorescence	 in	 situ	hybridization	 (FISH).	While	11q	and	17p	 deletions	 have	 been	 associated	 with	 rapid	 disease	 progression,	the	 absence	 of	 chromosomal	 abnormalities	 and	 the	 presence	 of	 13q	deletion	 as	 the	 sole	 abnormality	 are	 associated	 with	 a	 better	prognosis24.	 The	 presence	 of	 chromosome	 alterations	with	 high	 risk	justifies	 the	 use	 of	 more	 aggressive	 treatment25.	 Chromosome	alterations	 are	 independent	 from	 IgVH	 mutational	 status	 though	 is	evident	a	more	frequency	of	11q-	and	17p-	in	unmutated	and	13q-	in	mutated	 cases.	 These	 data	 show	 that	 analysis	 conducted	 by	cytogenetic	 could	 be	 used	 as	 further	 risk	 stratification	 instrument	together	with	the	other	prognostic	factors26.			
Figure	8.	Time	to	Treatment	and	Overall	Survival	in	relationship	with	ZAP70	prognostic	marker.	The	median	time	to	treatment	and	overall	survival	 for	the	groups	with	high	 (ZAP70+)	or	 low	 (ZAP70-)	expression	of	this	protein.		
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	 5. Telomerase	expression	and	telomere	 length	 in	CLL.	 Activation	of	telomerase	 reverse	 transcriptase	 (hTERT)	 is	 essential	 for	 unlimited	cell	growth	and	plays	a	critical	 role	 in	 tumorigenesis27.	Recently,	 the	levels	 of	 telomerase	 activity	 (TA)	 and/or	 hTERT	 expression	 were	related	 to	 clinical	 aggressiveness	 and	 prognosis	 in	 a	 variety	 of	malignancies,	 including	 CLL.	 CLL	 cases	 with	 high	 telomerase	 levels	and	short	 telomeres	were	 frequently	characterized	by	an	unmutated	IgVH	status	and	high-risk	chromosomal	aberrations.	Conversely,	CLL	cases	with	low	telomerase	levels	and	long	telomeres	were	associated	with	 a	mutated	 IgVH	 status	 and	 low-risk	 abnormalities	 (Figure	 10).	The	evaluation	of	hTERT	and	telomere	length	might	help	the	clinician	vin	 the	 management	 of	 CLL	 patients	 with	 mutated	 IgVH	 and/or	 no	high-risk	 chromosomal	 aberrations	 since	 cases	 with	 high	hTERT/short	 telomere	 CLL	 will	 progress	 more	 rapidly	 and	 might	require	therapy	earlier	than	those	with	low	hTERT/long	telomeres28.			 							
Figure	 9.	 Time	 to	 treatment	 and	 probability	 of	 survival	 among	 patients	 in	 the	 most	 common	
chromosomal	alterations.	 The	median	 survival	 times	 and	 time	 to	 treatment	 for	 the	 groups	with	 17p	deletion,	11q	deletion,	12q	trisomy,	normal	karyotype,	and	13q	deletion	as	single	abnormality	were	0.18,	1.75,	3.81,	11.56,	and	8.00	years,	respectively	(adapted	from	Visentin	et	al)26.	
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1.5	Treatment		 			 Criteria	for	initiating	treatment	depend	on	clinic	symptoms,	stage	and	disease	 activity.	 Treatment	 should	 only	 be	 initiated	 in	 patients	 with	symptomatic,	active	disease.	Significant	B	symptoms,	cytopaenias	not	caused	by	 autoimmune	 phenomena	 and	 symptoms	 or	 complications	 from	lymphadenopathy,	 splenomegaly	 or	 hepatomegaly,	 lymphocyte	 doubling	time	of	<6	months	(only	in	patients	with	more	than	30x109	lymphocytes/l),	as	 well	 as	 autoimmune	 anaemia	 and/or	 thrombocytopaenia	 poorly	responsive	 to	 conventional	 therapy	 define	 an	 active	 disease29.	 In	 general	practice,	 newly	 diagnosed	 patients	 with	 asymptomatic	 early-stage	 disease	(Rai	 0,	 Binet	 A)	 should	 be	 monitored	 without	 therapy	 unless	 they	 have	evidence	of	progression.	On	the	contrary,	patients	at	 intermediate	(I	and	II)	and	high	risk	stages	(III	and	IV),	according	to	the	modified	Rai	classification	or	at	Binet	stage	B	or	C,	usually	benefit	from	the	start	of	a	treatment;	some	of	these	patients	(in	particular	Rai	intermediate	risk	or	Binet	stage	A/B)	can	be	monitored	 without	 therapy	 until	 they	 have	 evidence	 for	 progressive	 or	symptomatic	disease11.	 	
Figure	10.	Curves	of	treatment-free	survival.	Time	from	diagnosis	to	first	treatment	(TTFT)	according	to	 IgVH	mutational	 status,	 chromosomal	 categories,	 and	 hTERT	 level/telomere	 length	profile	 (adapted	from	Rampazzo	et	al)28.		
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Figure	11.	Possible	decisional	pattern	in	CLL	treatment.	Indication	for	first	line	treatment	(A)	and	for	relapse	 or	 refractory	 disease	 (B).	 R	 (rituximab),	 Clb	 (chlorambucil),	 F	 (fludarabine),	 C	(cyclophosphamide),	B	(bendamustine)	and	alloHSCT	(allogenic	hematopoietic	stem	cell	transplantation)	(adapted	from	Eichhorst	et	al)29.	
A 
B 
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Therapeutic	 possibilities	 comprehend	 drugs	 with	 different	mechanisms	of	 action,	up	 to	 stem	cells	 auto/allotransplantation.	Treatment	possibilities	 include	 both	 drugs	 with	 different	 mechanisms	 of	 action	 and	auto/allogeneic	stem	cell	transplantation.	In	any	case,	because	of	the	indolent	nature	of	the	disease,	the	therapy	does	not	aim	to	complete	recovery,	that	is	the	 elimination	 of	 the	 leukemic	 clone,	 but	 to	 control	 the	 expansion	 of	neoplastic	cells.	The	 choice	 of	 the	 therapy	 is	 linked	 to	 patient	 age	 and	 general	conditions.		In	physically	fit	patients	(physically	active,	with	no	major	health	problems,	 normal	 renal	 function)	 without	 TP53	 deletion/mutation,	 FCR	 is	the	 standard	 first-line	 therapy:	 improvement	 of	OS	has	 been	demonstrated	with	this	first-line	chemoimmunotherapy	(Figure	11	A)30.	In	 patients	 with	 relevant	 co-morbidity,	 who	 are	 usually	 older,	 but	without	 TP53	 deletion/mutation,	 the	 combination	 of	 chlorambucil	 plus	 an	anti-CD20	 antibody	 (rituximab,	 ofatumumab	 or	 obinutuzumab)	 prolongs	progression-free	 survival	 (PFS)	 when	 compared	 with	 monotherapy	 and	 is	therefore	the	standard	approach31.	First-line	 treatment	 may	 be	 repeated	 if	 the	 relapse	 or	 progression	occurs	 at	 least	 24-36	 months	 after	 chemoimmunotherapy	 and	 if	 TP53	deletion/mutation	was	excluded.	If	relapse	occurs	within	24-36	months	after	chemoimmunotherapy,	 or	 if	 the	 disease	 does	 not	 respond	 to	 any	 first-line	therapy,	the	therapeutic	regimen	should	be	changed	(Figure	11	B)29.		In	 addition	 to	 cytoreductive	 therapy,	 CLL	 treatment	 includes	substitutive	and	support	therapy,	such	as	red	cells	and	platelets	transfusions,	antibiotic	therapy,	and	intravenous	immunoglobulin	administrations.		
2.	Neoplastic	B	lymphocytes			 CLL	is	a	disease	characterized	by	an	extremely	heterogeneous	clinical	course,	 despite	 a	 substantial	 morphologic	 and	 immunophenotypic	uniformity.		 B	 cells	 are	 lymphocytes	 that	 participate	 in	 humoral	 immunity	 by	producing	antibodies	(Abs)	in	response	to	antigen	(Ag)	stimulation.	They	can	
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differentiate	 from	 "naive"	 lymphocytes	 to	 cells	 secreting	 antibodies	 against	specific	 antigens	 (plasma	 cells),	 or	 to	 "memory"	 long-lived	 stimulated	 B	lymphocytes	that	are	ready	for	rapid	response	to	a	repeated	exposure	of	the	priming	antigen.			 The	 B-Cell	 Receptor	 (BCR)	 mediates	 antigen	 recognition.	 BCR	 is	 a	multimeric	 complex	 composed	 by	 an	 sIg	 homodimer	 that	 is	 linked	 to	plasmatic	 membranethrough	 its	 constant	 region	 (crystallizable	 fragment,	Fc)32,33;	 the	 sIg	 antigen	 binding	 region	 (Fab)	 is	 outward	 and	 noncovalently	linked	to	Igα/Igβ	(CD79a/CD79b)	heterodimer,	deputy	to	intracellular	signal	transduction34	(Figure	12).	The	Fab	region	comprehends	variable	regions	(V)	of	sIg	light	and	heavy	chains	that	give	BCR	specificity	for	a	specific	antigen.	In	turn,	 V	 regions	 are	 composed	 by	 three	 ipervariable	 regions,	 called	"complementarity	 determining	 regions"	 (CDR)	 that	 allow	 high	 affinity	binding	with	the	antigen.		
	 	What	 differentiates	 a	 "naive"	 B	 lymphocyte	 from	 a	 "memory"	 B	lymphocyte	is	the	fact	that	the	"naive"	one	presents	an	amino	acid	sequence	identical	to	"germline"	sequence,	while	the	"memory"	one	is	characterized	by	
Figure	12.	Schematic	representation	of	the	BCR.		BCR	is	composed	of	two	immunoglobulin	(Ig)	heavy	and	 light	 chains	 (variable	 and	 constant	 regions),	 and	 CD79a	 and	 CD79b	 (Igα/Igβ),	 which	 contain	 an	intracellular	 activation	motif	 that	 transmits	 signals	 to	 intracellular	 tyrosine	 kinases	 (for	 example,	 SYK	and	Lyn)	(adapted	form	Abbas		et	al)33.	
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a	 different	 sequence.	 This	 is	 due	 to	 somatic	 hypermutation	 process	 that	underlies	the	phenomenon	of	affinity	maturation.			 Once	recognized	a	specific	antigen,	the	"naive"	B	lymphocyte	turns	on	and	 begins	 to	 proliferate	 inside	 lymphoid	 organs.	 Some	 of	 this	 progeny	enters	 the	 lymphoid	 follicles	 and	 forms	 the	 germinal	 centre	 (GC)	characterized	 by	 an	 intense	 proliferation.	 Here,	 Ig	 genes	 undergo	 point	mutations	that	lead	to	the	formation	of	clones	with	different	affinities	for	the	antigen.	 Clones	 are	 selected	 through	 contact	 with	 follicular	 dendritic	 cells	expressing	 antigen:	 lymphocytes	 that	 bind	 antigen	 with	 greater	 affinity	survive,	while	others	undergo	apoptosis35.	
	 	CLL	 lymphocytes	 are	 small	 "memory"	 B	 cells	 blocked	 in	 G0/G1	 and	characterized	 by	 surface	 markers	 recognized	 by	 specific	 monoclonal	antibodies;	 some	 of	 these	markers,	 such	 as	 CD19	 and	 CD21,	 are	 B-related,	while	others,	like	CD5,	CD23,	CD25,	and	HLA-DR	(human	Leukocyte	Antigen	D-related),	are	not	specific	for	B	lymphocytes.	In	particular,	CLL	cells	express	
Figure	 13.	 Pathogenesis	 of	 CLL.	 Current	 thinking	 is	 that	 mutated	 CLL	 cells	 derive	 from	 a	 post-germinal	center	memory	B	cell,	while	not	changed	one	from	a	B	cell,	which	however	has	been	activated	from	the	antigen;	it	is	unclear	if	involving	the	naïve	B	lymphocyte,	the	CD5	+	B1	or	marginal	zone	B	one.	Image	from	Zen	et	al35.		
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markers	 typical	of	mature	B	cells	 localized	 in	 the	mantle	zone	of	secondary	lymphoid	follicles.		 Recent	studies	have	shown	that	50-70%	of	CLL	have	undergone	IgVH	hypermutation,	a	phenomenon	that	characterizes	normal	B	cells	subjected	to	a	 T	 cell-dependent	 GC	 reaction.	 This	 finding	 has	 led	 to	 the	 hypothesis	 that	CLL	cases	displaying	mutated	IgVH	may	derive	from	a	cell	that	had	transited	through	 the	 GC,	whereas	 those	with	 germline	 IgVH	may	 derive	 from	 a	 GC-independent	cells.	This	hypothesis	has	both	biological	and	clinical	relevance	since	 the	 two	 subgroups	have	different	 prognosis,	with	M-CLL	displaying	 a	better	clinical	course36.		The	 factors	 involved	 in	 CLL	 pathogenesis	 comprehend	 control	 of	apoptosis,	 signal	 transduction	 BCR-mediated,	 proliferative	 activity	 and	 the	microenvironment.		
2.1	Intrinsic	Factor	-	Control	of	apoptosis			 The	 dysregulation	 of	 the	 process	 of	 programmed	 cell	 death	(apoptosis)	 is	now	widely	 recognized	as	one	of	 the	main	mechanism	 in	 the	pathogenesis	of	many	tumors.	The	accumulation	of	CLL	cells	is	related	to	the	fact	 that	 they	 do	 not	 undergo	 apoptosis,	 thus	 failing	 the	 homeostatic	mechanism	that	normally	limits	the	number	of	circulating	cells.		Malignant	B	cells	retain	the	ability	to	respond	to	microenvironmental	signals,	 but	 have	 devised	 a	 monothematic	 responsiveness.	 They	 have	 a	specific	 sensitivity	 to	 anti-apoptotic	 signals	 that	 favour	 their	 survival	 and	become	insensitive	to	pro-apoptotic	signals21.			Apoptosis	may	be	triggered	through	2-way	(Figure	10)37:	1. in	 the	 extrinsic	 way,	 death	 extracellular	 signals	 (FASL,	 TNF,	 TRAIL)	are	 transduced	 by	 surface	 receptors	 (FAS,	 TNFR)	 and	 the	 adapter	protein	FADD	activate	pro-caspase-8;	2. in	 the	 intrinsic	 way	 factors	 such	 as	 DNA	 damage,	 the	 presence	 of	reactive	 oxygen	 species,	 pro-apoptotic	 signals	 and	 mitochondrial	damage,	stimulate	the	release	of	cytochrome	C	into	the	cytosol	where	complex	with	APAF-1	and	pro-caspasi	9	forming	the	apoptosome38.	
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	With	respect	to	intrinsic	factors,	the	balance	between	pro-	and	anti-apoptotic	factors	is	very	important.	Among	these,	the	principal	apoptosis	regulators	are	proteins	 of	 the	Bcl-2	 family	 (B-cell	 lymphoma-2	 factors)	 that	 play	 a	 crucial	role	in	this	mechanism	by	inhibiting	(Bcl-2,	Bcl-xL,	Bcl-w,	Bfl-1,	and	Mcl-1)	or	promoting	(Bax,	Bak,	Bcl-xS,	Bid,	Bik,	and	Hrk)	apoptosis.	Heterodimerization	between	 pro-	 and	 anti-apoptotic	 members,	 and	 their	 relative	 levels,	 may	determine	 the	 predisposition	 to	 respond	 to	 a	 given	 apoptotic	 stimulus	(Figure	 14).	 Many	 investigators	 have	 reported	 altered	 expression	 of	 Bcl-2,	Bax,	and	Mcl-1	in	CLL39.		
Figure	14.	The	molecular	mechanisms	of	apoptosis.	Apoptosis	pathways	can	be	initiated	via	different	stimuli,	 that	 is,	 at	 the	 plasma	 membrane	 by	 death	 receptor	 ligation	 (extrinsic	 pathway)	 or	 at	 the	mitochondria	 (intrinsic	 pathway).	 Stimulation	 of	 death	 receptors	 results	 in	 receptor	 aggregation	 and	recruitment	of	 the	 adaptor	molecule	Fas-associated	protein	with	 death	domain	 (FADD)	and	 caspase-8.	Caspase-8	 initiates	 apoptosis	 by	 direct	 cleavage	 of	 downstream	 effector	 caspases.	 Mitochondria	 are	engaged	 via	 the	 intrinsic	 pathway,	 which	 can	 be	 initiated	 by	 a	 variety	 of	 stress	 stimuli,	 including	ultraviolet	(UV)	radiation,	γ-irradiation,	heat,	DNA	damage,	the	actions	of	some	oncoproteins	and	tumour	suppressor	 genes	 (i.e.	 p53),	 viral	 virulence	 factors,	 and	 most	 chemotherapeutic	 agents.	 CAD,	 caspase	activated	DNase;	FAS,	fibroblast	associated	antigen.	ICAD,	inhibitor	of	CAD;	ROS,	reactive	oxygen	species;	TNF,	tumour	necrosis	factor;	TRAIL,	TNF	related	apoptosis	inducing	ligand38.	Image	from	de	Vries	et	al37.	
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	 Other	 intrinsic	 factors,	 critical	 for	 apoptosis	 control,	 are	 17p13	 and	11q23	deletions	containing	2	prominent	tumor-suppressor	genes	mutated	at	varying	proportions:	TP53	(tumor	protein	53)	and	ATM	(Ataxia	telangiectasia	mutated),	respectively.	Mutations	of	TP53	and	ATM,	even	in	the	absence	of	a	chromosomal	 deletion,	 have	 been	 identified	 to	 have	 adverse	 effects	 on	patient	 survival.	 p53	 and	 ATM	 proteins	 are	 central	 regulators	 of	 the	 DNA-damage-response	pathway	and	their	activation	leads	to	cell-cycle	arrest	and	DNA	 repair,	 apoptosis,	 or	 senescence,	 depending	 on	 the	 cellular	 context.	Impaired	 p53	 function	 through	 mutations	 and/or	 deletions	 is	 the	 best-characterized	factor	associated	with	chemoresistance	in	CLL40.			 Moreover,	 TOSO,	 also	 known	 as	 Fas-inhibitory	 molecule	 3,	 was	identified	as	a	candidate	gene	overexpressed	in	CLL.		 TOSO	 is	 a	 transmembrane	 protein	 that	 inhibits	 Fas-mediated	apoptosis	by	binding	Fas-associated	death	domain	(FADD)	via	its	C-terminal	intracellular	 domain.	 In	 CLL,	 high	 levels	 of	 TOSO	 expression	 have	 been	correlated	with	a	more	aggressive	disease41.		
2.2	Intrinsic	Factor	-	BCR-mediated	signal	transduction		For	 effective	 humoral	 immunity,	 mature	 B	 cells	 must	 respond	 to	 foreign	antigens	 and	 generate	 antigen-specific	 effector	 cells;	 so,	 it	 is	 not	 surprising	that	 the	 BCR	 complex	 is	 required	 for	 the	 later	 stages	 of	 B-cell	maturation.	BCR	has	 two	main	 roles:	 the	 first	 is	 to	 transmit	 signals	 that	 regulate	B-cell	fate	decision	and	the	second	is	to	mediate	antigen	processing	leading	to	the	presentation	of	antigen	to	T	cells,	which	allows	full	activation	of	B	cells	in	the	effector	phase.	The	BCR	complex	consist	of	immunoglobulin	heavy	(IgH)	and	light	 (IgL)	 chains	 associated	 with	 Igα	 and	 Igβ	 containing	 ITAM	(Immunoreceptor	 Tyrosine-based	 Activation	 Motif)	 domains.	 After	 BCR	ligation	by	antigen,	both	the	protein	tyrosine	kinases	(PTKs)	Syk	and	Lyn	are	activated42.	 Then,	 Lyn	 phosphorylates	 ITAMs	 which,	 in	 turn,	 recruit	 and	facilitate	 the	 activation	 of	 Syk	 and	 Tec-family	 PTKs.	 This	 phosphorylation	results	 in	 the	 recruitment	 of	 other	 molecules	 involved	 in	 BCR-mediated	signal	transduction	(Figure	15)35.		
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BCR	signaling	can	be	also	regulated	by	the	membrane	organization	of	signaling	 components.	 Literature	 data	 proposed	 that	 in	 the	 absence	 of	antigen	binding,	 the	BCR	 is	already	pre-assembled	 into	oligomeric	 receptor	complexes,	 which	 generate	 a	 basal	 level	 of	 signaling	 essential	 for	 B-cell	maintenance43.	The	low	levels	of	sIgs	may	explain	the	reduced	ability	of	CLL	cells	 to	capture,	present,	and	respond	 to	antigen.	Defects	 in	 the	BCR	of	CLL	have	 been	 attributed	 to	 functional	 deficiency	 in	 the	 CD79	 heterodimer,	especially	CD79b,	which	is	expressed	at	low	levels	on	these	tumor44.		During	B	cells	activation	process,	an	important	function	is	carried	out	by	 plasma	 membrane	 microdomains	 called	 lipid	 rafts.	 These	 domains	 are	rich	 in	 glycosphingolipids	 and	 cholesterol	 which	 create	 a	 liquid-ordered	phase	 within	 the	 plasma	 membrane.	 Lipid	 rafts	 are	 fluid	 at	 physiological	temperatures,	 allowing	 lateral	 diffusion	 of	 proteins	 and	 lipids	 within	 the	
Figure	 15.	 BCR-induced	 signal	 transduction	 pathways.	 After	 antigen	 ligation,	 tyrosine-kinase	 Lyn	phosphorylates	ITAMs	of	 Igα	and	Igβ,	creating	binding	sites	to	protein	SH2	domain,	such	as	Syk	kinase.	Follow	 different	 biochemical	 reactions	 that	 culminate	 in	 the	 B	 cell	 activation,	 differentiation	 and/or	proliferation.	Image	from	Zen	et	al35.	
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plane	 of	 the	 membrane.	 In	 addition,	 they	 are	 constitutively	 enriched	 in	certain	types	of	proteins	such	as	glycosphingolipids-linked	proteins	and	lipid	chain-modified	proteins,	including	heterotrimeric	G	proteins,	the	Src	kinases	Lyn	 and	 Fyn,	 and	 other	molecules	 involved	 in	 signal	 transduction,	 such	 as	Blk,	Ras,	c-Abl,	and	actin45.			 Additional	proteins,	like	CD45	and	Syk,	seem	to	be	excluded	from	raft	and	recruited	only	after	BCR	translocation	into	them	after	the	engagement	by	the	Ag.	In	fact,	according	to	the	most	recent	model	proposed	to	explain	BCR	functions	 in	 the	 activation	 of	 B	 cells,	 in	 resting	 B	 cells	 the	 BCR	 is	 initially	excluded	 from	 lipid	 rafts;	 once	having	bound	 the	 antigen,	BCR	 translocates	into	the	rafts	thus	starting	the	signal	transduction	cascade.	Lyn	 is	 a	 Src-family	 tyrosine	kinase,	which,	with	Blk	 and	Fyn	Src-like	kinases,	 is	 necessary	 for	 BCR	 signaling	 considering	 its	 role	 in	phosphorylation	 of	 the	 ITAM	 on	 Igα/Igβ.	 Tyrosine	 phosphorylated	 Igα/Igβ	recruits	 Syk	 via	 the	 latter’s	 tandem	 SH2	 domains	 leading	 to	 downstream	signaling	 events.	 Lyn	 also	 provide	 feedback	 inhibition	 of	 BCR	 signaling	 by	phosphorylation	 of	 cell	 surface	 proteins	 containing	 immunoreceptor	tyrosine-based	 inhibitory	 motifs	 (ITIMs).	 These	 ITIM-containing	 inhibitory	receptors	 include	 the	 inhibitory	 Fc	 receptor	 for	 IgG,	 FcγRIIb,	 and	 the	 sialic	acid-binding	 protein	 expressed	 on	 B	 cells,	 CD22.	 The	 phosphorylation	 of	these	 ITIMs	 generates	 binding	 sites	 for	 the	 membrane	 recruitment	 of	phosphatases	 that	 inhibit	 BCR	 signaling,	 including	 the	 SH2-domain-containing	 inositol	 phosphatase	 (SHIP-1)	 and	 the	 SH2-domain-containing	tyrosine	 phosphatase	 (SHP-1).	 The	 net	 result	 of	 Lyn-deficiency	 is	 an	exaggerated	signaling	by	the	BCR,	a	phenotype	that	is	moderate	in	immature	B	 cells	 and	 highly	 pronounced	 in	 mature	 follicular	 B	 cells.	 Lyn	 also	 acts	inhibiting	 receptor	 signaling	 in	 myeloid	 cells	 and	 recent	 studies	demonstrated	 that	 hyperactivity	 of	myeloid	 cells	 contributes,	 in	 a	 relevant	manner,	to	autoimmunity	in	Lyn-/-	mice46.	In	B	lymphocytes,	Lyn	may	also	be	associated	 to	 the	 non-receptor	 tyrosin-kinase	 Fak	 (Focal	Adhesion	Kinase),	involved	 in	 different	 signal	 transduction	 cascades.	 This	 complex	 may	contribute	to	cytoskeletal	reorganization	after	antigen	binding47.	
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Our	group	demonstrated	 that	 in	CLL,	as	compared	 to	normal	B	cells,	protein	 Lyn	 is	 upregulated	 and	 shows	 a	 different	 subcellular	 localization48.	Moreover,	Lyn	displays	a	remarkable	constitutive	activity,	which	leads	to	an	increased	basal	 tyrosine	protein	phosphorylation	and	a	 low	responsiveness	to	 BCR	 ligation.	Whereas	 Lyn	was	 concentrated	 in	membrane	 lipid	 rafts	 in	normal	B	cells,	the	enzyme	was	present	all	over	the	cell	surface	membrane	in	CLL	cells.	Lyn	was	also	detected	 in	the	cytosol	of	 the	malignant	B	cells.	The	release	of	Lyn	 into	 the	cytosol	 following	caspase-dependent	cleavage	of	 the	tyrosine	kinase	at	its	N-terminus	has	been	described	as	a	general	mechanism	in	hematopoietic	cells	during	BCR-induced	apoptosis49.		The	findings	that	CLL	cells	 contain	 a	 cytosolic	 Lyn	 fraction	 and	 are	 defective	 in	 programmed	 cell	death	suggest	 that	 the	tyrosine	phosphorylation	of	specific	cytosolic	 targets	might	account,	at	least	in	part,	for	cell	resistance	to	apoptosis.			 The	 activity	 of	 Lyn	 is	 critically	 regulated	 through	 its	 C-terminal	Tyr507,	 which	 is	 phosphorylated	 by	 the	 tyrosine	 kinase	 Csk	 and	dephosphorylated	by	 the	 receptor	 tyrosine	phosphatase	CD45.	 In	 resting	B	lymphocytes,	 Lyn	 is	 present	 in	 its	 inactive	 conformation,	 as	 result	 of	 Csk	phosphorylation	of	Tyr507,	which	gives	rise	to	an	intramolecular	association	of	 the	 phosphorylated	 residue	 with	 Lyn’s	 own	 SH2	 domain50.	 Since	 Csk,	unlike	Lyn,	was	similarly	expressed	in	normal	and	CLL	cells,	the	constitutive	activity	of	Lyn	could	be	due	to	the	fact	that	the	amount	of	Csk	is	insufficient	to	phosphorylate	and	down	regulate	its	overexpressed	substrate.	However,	it	is	likely	that	other	factors	are	responsible	for	the	presence	of	the	active	form	of	Lyn	in	CLL	cells,	first	among	which	might	be	the	dephosphorylation	of	Lyn	at	 Tyr507	 by	 the	 tyrosine	 phosphatase	 CD45,	 an	 abundant	 membrane	protein	 that,	 in	normal	B	cells,	has	access	 to	Lyn	only	after	 its	migration	 to	lipid	 rafts	 induced	 by	 BCR	 engagement45.	 Furthermore,	 the	 high	concentration	 of	 Lyn	 in	 CLL	 cells	 could	 promote	 the	 kinase	 intermolecular	autophosphorylation	at	Tyr396,	which	in	turn	induces	Lyn	activation51.			 It	 is	 known	 that,	 after	 activation,	 Src	 Family	 Kinase	 (SFK)	 level	 is	regulated	 by	 the	 balance	 of	 two	 opposing	 mechanisms:	 degradation	 by	ubiquitinylation	or	rescue	by	association	with	Hsp90	(Heat	shock	protein	of	90kDa),	a	chaperone	interacting	with	the	N-terminal	lobe	of	the	SFK	catalytic	
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domain52.	 Recently,	 we	 demonstrated	 that,	 in	 CLL	 cells,	 Lyn	 is	 an	 integral	component	 of	 an	 aberrant	 cytosolic	 600kDa	 complex,	 where	 Lyn	 is	associated	both	with	Hsp90	through	its	catalytic	domain,	HS1	(Hematopoietic	lineage	cell	Specific	protein	1),	and	SHP-1	through	its	SH3	domain.	Moreover,	Hsp90	 stabilizes	 the	 complex	 by	 contributing	 to	 converting	 a	 network	 of	transient	interactions	into	permanent	ones,	thus	maintaining	Lyn	in	an	active	conformation	and	preventing	its	degradation53.			 HS1,	 one	 of	 the	most	 important	 Lyn	 substrate,	 is	 an	 F-actin	 binding	protein	 involved	 in	 the	 apoptosis	 of	 several	 hematopoietic	 cell	 lines.	 HS1	phosphorylation	 occurs	 in	 a	 sequential	model	mediated	 by	 Syk	 and	 Lyn.	 It	seems	that	tyrosin-phosphorylation	of	cortactin,	an	HS1	homologous	protein	involved	in	cell	motility,	occur	by	the	same	mechanism	of	recruitment	of	the	SFKs.		 PI3K	and	PLCγ2	are	both	 crucial	 effector	enzymes	 that	generate	key	second	 messengers	 in	 BCR	 signaling.	 PI3K	 phosphorylates	phosphatidylinositol-4,5-bisphosphate	 (PtdInsP2)	 to	 produce	phosphatidylinositol-3,4,5-trisphosphate	(PtdInsP3),	which,	 in	 turn,	recruits	some	BCR	signaling	molecules	to	the	membrane	through	PH	domains.	PLCγ2	uses	 PtdInsP2	 to	 generate	 inositol-1,4,5-trisphosphate	 (InsP3)	 and	diacylglycerol	 (DAG),	 which	 are	 required	 for	 the	 release	 of	 intracellular	calcium	 (Ca2+)	 and	 activation	 of	 protein	 kinase	 C	 (PKC),	 respectively.	Subsequently,	Ca2+	flux	and	PKC	activation	induce	the	activation	of	mitogen-activated	 protein	 kinase	 (MAPK)-family	 kinases,	 extracellular	 signal-regulated	 kinase	 (ERK),	 c-JUN	 NH2-terminal	 kinase	 (JNK),	 p38	 MAPK,	 and	transcription	factors,	including	nuclear	factor-κB	(NF-κB)	and	nuclear	factor	of	activated	T	cells	 (NFAT).	 It	 is	probable	 that	 the	profile	of	 these	activated	transcription	factors	then	determines	B	cell	fate.		 Non-enzymatic	adaptor	proteins	are	also	important	in	regulating	BCR	signaling.	Among	them,	B	cell	linker	(BLNK)	efficiently	connects	Syk	and	Btk	with	 PLCγ2.	 Disruption	 of	 the	 BLNK	 gene	 leads	 to	 impaired	 activation	 of	PLCγ2	 in	 B	 cells;	 BLNK	 also	 associates	 with	 Vav	 and	 Nck,	 both	 of	 which	regulate	cytoskeletal	organization	in	B	cells.	
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	 Another	 B-cell	 adaptor,	 B	 lymphocyte	 adaptor	 molecule	 of	 32kDa	(BAM32),	also	binds	PLCγ2	and	regulates	 its	activation.	Since	 it	 is	recruited	to	 the	membrane	 in	a	PI3K-dependent	manner,	BAM32	 integrates	 the	PI3K	and	 PLCγ2	 pathways.	 The	 B	 cell-specific	 co-receptor	 CD19	 can	work	 as	 an	adaptor	for	PI3K	also	in	B	cells.		 In	mature	B	cells,	BCR	associates	with	 lipid	raft	after	Ag	engagement	and	the	signal	transduction	induces	transcription	of	genes	responsible	for	B	cell	activation.	Then,	the	BCR	is	internalized	and	can	be	degraded	or	sent	to	an	 intracellular	 compartment	 called	 MIIC	 (MHC-class-II-peptide-loading-compartment)	 where	 Ag	 processing	 and	 the	 synthesis	 of	 peptide-MHC	complexes	 to	 Ag	 presentation	 occur.	 	 These	 complexes	 are	 brought	 to	 cell	surface,	 presented	 to	T	 cells	 and	 then	 recognized	by	TCR	of	Th	 cells	which	activate	B	cells	through	cytokines	release.			 In	 immature	 B	 cells,	 BCR	 is	 excluded	 from	 lipid	 rafts	 even	 after	 Ag	binding	and,	in	this	case,	cell	apoptosis	is	induced.	A	behavior	similar	to	that	of	immature	B	cells	is	described	also	to	cells	rendered	tolerant	or	anergic	by	chronic	exposure	to	Ag:	BCR	is	still	excluded	from	rafts	even	after	Ag	binding	and	 the	 result	 is	 the	 lack	 of	 a	 cellular	 response.	 Conversely,	 in	 B	 pre-lymphocytes	a	significant	proportion	of	BCR	and	signaling	molecules,	such	as	PLCγ2	 and	 PI3K,	 are	 constitutively	 associated	with	 rafts	 and	 this	 seems	 to	generate	signals	of	survival	and	cell	differentiation.	In	these	cases,	molecule	such	 as	 PI3K,	 RAS,	 RAF,	 ERK	 and	 NF-κB	 are	 fundamental	 in	 signal	transduction	 in	 association	 with	 BCR.	 PI3K	 activates	 and	 phosphorylates	Akt/PKB	 which,	 in	 turn,	 phosphorylate	 cellular	 targets	 involved	 in	 cell	survival	 including	apoptotic	 factors	and	glycogen	metabolism.	One	 function	of	Akt	 is	 to	 inhibit	 the	activation	of	 the	pro-apoptotic	Bcl-2-family	member	BAD	 (Bcl-2	 antagonist	 of	 cell	 death);	 moreover,	 Akt	 phosphorylates	 and	inhibits	 glycogen	 synthase	kinase	3	 (GSK3)	 in	B	 cells.	 In	unstimulated	 cells	GSK3	 is	 constitutively	 active;	 it	 phosphorylates	 and	 destabilizes	 Myc	 and	cyclin	D,	both	of	which	are	required	for	cell-cycle	progression.	In	this	way,	it	seems	that	Akt	 functions	 to	promote	BCR-induced	cell	proliferation,	as	well	as	survival42.					
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2.4	Extrinsic	Factor	-	Microenvironment		 Despite	 their	 in	vivo	 prolonged	 lifespan	due	 to	 intrinsic	 defects,	 also	sustained	 by	 the	 over-expression	 and	 constitutive	 activation	 of	 Src	 kinase	Lyn48,	 CLL	 leukemic	 cells	 rapidly	 undergo	 spontaneous	 apoptosis	 in	 vitro,	highlighting	the	need	of	extrinsic	signals	delivered	by	the	microenvironment.	In	 fact,	 at	 the	 active	 sites	 of	 disease,	 such	 as	 bone	 marrow	 (BM)	 and	secondary	lymphoid	tissues,	CLL	cells	engage	complex	cellular	and	molecular	interactions	 with	 stromal	 cells	 that	 affect	 their	 survival,	 growth	 and	 often	confer	drug-resistance54.		Among	bone	marrow	stromal	cells,	mesenchymal	stromal	cells	(MSCs)	show	a	bidirectional	cross-talking	with	neoplastic	B	cells.	Leukemic	cells	are	supported	by	stromal	cells	and,	 in	turn,	are	also	able	to	activate	and	induce	stromal	 cell	 to	 proliferate	 and	 release	 several	 mediators	 (i.e.,	 CXCL12,	CXCL13,	CCL19	and	CCL21)	which	sustain	the	ongoing	process55,56.	Although	 in	 healthy	 subjects	MSCs	 represent	 a	 small	 fraction	 of	 the	stromal	 cell	 population,	 immunohistochemistry	 studies	 showed	 that	 in	situ	αSMA+	mesenchymal	 stromal	 cells,	which	 represent	 the	 in	vivo	counterpart	of	 MSCs,	 are	 the	 dominant	 stromal	 cell	 population	 in	 CLL	microenvironment57;	 thus	 suggesting	 a	 MSC	 crucial	 role	 on	 favouring	malignant	cells	and	disease	progression.	The	interactions	between	MSCs	and	neoplastic	 B	 cells	 can	 occur	 both	 through	 direct	 cell-cell	 contact	 and	 via	soluble	factors	secreted	by	the	microenvironment58.	Bone	marrow	 precursors	 derived	 from	 pluripotent	 stem	 cells	 are	 in	contact	with	stromal	cells	and	generate	B	cells	in	an	Ag-independent	process.	BM	precursors	 differentiate	 to	mature	 virgin	B	 lymphocytes	 endowed	with	membrane	 Ag	 receptors	 that	 migrate	 to	 peripheral	 lymphoid	 tissues	searching	an	Ag.	The	encounter	with	a	 foreign	Ag	 triggers	B	cell	 activation,	proliferation,	 and	 a	 second	wave	 of	 differentiation.	 The	microenvironment	for	the	active	social	life	of	a	mature	B	cell	is	provided	by	the	germinal	centres	of	secondary	lymphoid	organs.	It	is	within	GC	that	trafficking	mature	B	cells	are	 brought	 into	 close	 contact	 with	 specialized	 T	 cells	 and	 Ag-presenting	cells.	 This	 dialogue,	 finely	 regulated	 by	 cytokines,	 adhesion	 structures,	 and	
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surface	molecules,	leads	to	the	generation	of	B	memory	cells	and	plasma	cell	precursors	 and	 to	 the	 apoptotic	 elimination	 of	 inefficient	 or	 potentially	dangerous	 cells.	 As	 all	 normal	 B	 cells	 evolve	 and	 operate	 thanks	 to	microenvironmental	 cross-talks,	 it	 becomes	 consequent	 to	 ask	whether	 the	microenvironment	 may	 also	 influence	 the	 natural	 history	 of	 B	 cell	malignancies59.				 Isolated	 CLL	 cells	 undergo	 relatively	 rapid	 apoptosis	 in	 vitro.	 This	observation	 has	 led	 to	 the	 speculation	 that	 the	 microenvironment	 is	necessary	and/or	plays	a	pivotal	role	in	maintaining	the	enhanced	survival	of	CLL	 cells	 in	 vivo.	 Human	 bone	 marrow	 stromal	 cells	 (BMSCs)	 have	 been	demonstrated	to	support	the	survival	of	CLL	cells	when	both	cell	types	were	co-cultured	 in	 vitro.	 Further	 investigations	 have	 suggested	 that	 CLL	 cells	need	 to	 have	 intimate	 contact	 with	 BMSC	 in	 bone	marrow,	 with	 T	 cells	 in	lymph	 nodes,	 and	 with	 nurse-like	 cells	 (NLCs)	 in	 lymphatic	 tissues	 to	maintain	 survival60.	 Mesenchymal	 Stromal	 Cells	 (MSCs)	 from	 both	 normal	healthy	 donors	 and	 CLL	 patients	 were	 able	 to	 protect	 leukemic	 cells	 from	undergoing	 spontaneous	 and	 drug-induced	 apoptosis.	 Our	 data	 show	 that	CLL	 B	 cells	 are	 susceptible	 to	 the	 anti-apoptotic	 effect	 of	 MSCs,	 favoring	neoplastic	B	cell	survival	in	vitro	for	at	least	7	days61.	Close	contact	between	CLL	cells	and	MSCs	is	capable	to	mediate	the	most	effective	drug-resistance	and	it	is	this	latter	interaction	that	could	be	the	most	important	in	providing	a	niche	for	residual	CLL	cells	post	treatment.	We	have	demonstrated	that	the	analysis	 of	 the	 cleavage	 pattern	 of	 PARP	 protein	 detected	 in	 CLL	 patients	after	7	day	co-culture	with	MSCs	allowed	us	to	distinguish	patients	into	two	groups	 on	 the	 basis	 of	 their	 dependence/independence	 to	microenvironmental	 pro-survival	 stimuli.	 The	 first	 group	 is	 represented	 by	those	CLL	B	cell	samples	that	underwent	spontaneous	apoptosis	in	medium	alone,	but	were	rescued	from	apoptosis	following	exposure	to	MSCs.	On	the	contrary,	 the	second	group	identified	CLL	samples	whose	viability	was	high	when	cultured	both	in	medium	alone	and	in	the	presence	of	MSCs,	indicating	that	 these	 CLL	 clones	 were	 able	 to	 survive	 independently	 from	 signals	coming	from	the	microenvironment61.	
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Recent	studies	demonstrated	 the	significance	of	CD49d	(α4	 integrin)	in	the	prognosis	of	CLL	disease53,54	as	well	as	its	biological	role	of	regulating	matrix	metalloproteinase-9	(MMP-9)62	Chronic	B	cell	malignancies	and	bone	marrow	 microenvironment.	 These	 observations	 imply	 that	 α4β1	 integrin	could	be	a	critical	mediator	of	tight	interactions	between	MSCs	and	CLL	cells	and	MSC-mediated	CLL	protection.			 The	 signals	 delivered	 for	 normal	 B-lymphocytes	 by	 activated	 T-cells	through	 CD40L	 induce	 B-cell	 growth,	 differentiation,	 and	 rescue	 from	apoptosis.	In	contrast	to	normal	B	cells,	a	subset	of	CLL	cells	expresses	both	CD40L	 and	 its	 receptor,	 enabling	 an	 autocrine	 loop	by	which	CLL	 cells	 can	promote	 survival	 signals	 on	 their	 own.	 CD40	 stimulation	 of	 CLL	 cells	 had	been	 shown	 to	 prevent	 apoptosis	 and	 induce	 proliferation	 in	 vitro.	 It	 has	been	observed	a	correlation	between	levels	of	the	anti-apoptotic	protein	Bcl-2	 and	 survival	 induced	by	 stromal	 cell	 contact,	 suggesting	 a	mechanism	by	which	 stromal	 cells	 induce	 protection	 of	 CLL	 cells	 against	 spontaneous	apoptosis.		In	 contrast,	 it	 was	 found	 that	 normal	 CD5+	 B	 lymphocytes	 were	unable	 to	 survive	 in	 co-culture	 with	 stromal	 cells.	 Stromal	 cells	 can,	 in	addition,	 induce	survival	of	CLL	cells	by	stromal	cell-derived	 factor-1	 (SDF-1/CXCL12),	 which	 is	 a	 homeostatic	 chemokine	 that	 signals	 through	 the	CXCR4	 chemokine	 receptor	 and	 plays	 an	 important	 role	 in	 lymphopoiesis.	High-levels	of	SDF-1	are	constitutively	produced	by	stromal	cells	within	the	marrow,	the	primary	site	of	early	B	cell	differentiation.	CLL	cells	express	high	levels	of	the	CXCR4	surface	receptor,	and	undergo	chemotaxis	in	response	to	SDF-1.	 In	 addition,	 it	 has	 been	 demonstrated	 that	 marrow	 stromal	 cells	attract	 CLL	 cells	 via	 the	 chemokine	 receptor	 CXCR4,	 providing	 a	 possible	explanation	accounting	for	the	infiltration	of	marrow	by	CLL	cells55.	All	these	studies	demonstrated	the	importance	of	microenvironment:	MSCs	 co-culture	 represents	 a	 reproducible	 in	 vitro	 system	 with	 functional	similarities	 to	 in	 vivo	 bone	 marrow	 conditions,	 pointing	 out	 that	 the	heterogeneity	of	the	disease	is	reflected	also	in	CLL	B	cell	capacity	to	respond	to	favorable	signals	from	MSCs61.				
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3.	Janus	family	kinase/Signal	Transducer	and	Activator	of	
Transcription	pathway		 Several	signal	transduction	pathways	use	a	number	of	mediators	and	a	 series	 of	 proteins	 with	 function	 of	 receptor	 in	 order	 to	 transport	 the	information	 (transmitted	by	cytokines,	hormones	and	growth	 factors)	 from	the	 microenvironment	 into	 the	 cell.	 These	 molecules	 induce	 different	responses,	 including:	cell	proliferation,	survival,	differentiation	and	motility.	In	 order	 to	 act	 on	 cells,	 these	 factors	must	 interact	with	 specific	 receptors	able	to	transduce	the	signal	inside	the	cell;	the	most	important	receptors	are:		1. receptors	 with	 intrinsic	 tyrosine	 kinase	 activity	 (Receptor	 Tyrosine	Kinase,	RTK);		2. receptors	 consisting	 seven	 transmembrane	 domains	 coupled	 to	 G	proteins	(e.g.	the	receptors	for	chemokines);		3. receptors	for	cytokines.	Different	hormones	(e.g.	erythropoietin,	prolactin)	and	cytokines	(e.g.	IL-6)	 use	 receptors	 for	 cytokines	 not	 presenting	 intrinsic	 kinase	 activity	(differently	 from	 RTKs),	 but	 acquiring	 it	 upon	 binding	 with	 the	 specific	ligand;	this	interaction	enables	the	recruitment,	at	the	cytosolic	portion	of	the	receptor,	 of	 tyrosine	kinases	 that	 in	 turn	phosphorylate	 various	 substrates,	inducing	the	transduction	of	different	signals	(e.g.	proliferation,	survival,	etc.)	Among	the	signaling	pathways	activated	by	this	class	of	receptors,	one	of	 the	 most	 important	 is	 represented	 by	 tyrosine	 kinases	 of	 Janus	 family	(JAK)	 and	 the	 Signal	 Transducer	 and	 Activator	 of	 Transcription	 (STAT)	proteins.	 Previously	 four	 different	 JAKs	 (JAK1,	 JAK2,	 JAK3	 and	 TYK2)	 and	seven	 STATs	 (STAT1,	 STAT2,	 STAT3,	 STAT4,	 STAT5A,	 STAT5B	 and	 STAT6)	have	 been	 identified;	 through	 different	 combinations	 they	 are	 able	 to	mediate	signal	of	more	than	40	cytokines63.	The	 bond	 with	 the	 ligand	 induces	 the	 dimerization	 of	 the	 receptor	complex,	 resulting	 in	 a	 connection	 of	 the	 JAKs	 and	 in	 their	 cross-phosphorylation.		
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The	activated	JAK,	in	turn,	phosphorylates	the	cytoplasmic	domain	of	the	cytokine	receptor,	thus	recruiting	and	phosphorylating	STAT.	STAT,	once	phosphorylated,	 form	activated	dimers	 or	 tetramers	which	 translocate	 into	the	 cell	 nucleus	 where	 bind	 specific	 DNA	 sequences	 called	 STAT	 Binding	Elements	(SBE)	and	activate	the	expression	of	target	gene	(e.g.	Mcl-1,	Bcl-2,	SOCS3,	etc)	(Figure	16).	
	The	target	genes	of	this	pathway	are	genes	deputies	to	the	regulation	of	 cell	 growth,	 differentiation,	 proliferation,	 survival	 and	 apoptosis.	Deregulation	 of	 JAK/STAT	 signaling	 pathway	 may	 lead	 to	 inappropriate	activation	 of	 STAT	 and	 to	 its	 subsequent	 transformation	 in	 an	 oncogene	involved	in	tumor	development	of	hematopoietic	cells64.		Moreover,	there	are	three	classes	of	negative	regulators	of	JAK/STAT	pathway:	SOCS	(Suppressors	of	Cytokine	Signaling),	PIAS	(Protein	Inhibitors	of	Activated	STATs)	and	PTP	(Protein	Tyrosine	Phosphatases)65.	SOCS	proteins	belong	to	an	eight-member	family.	They	present	an	SH2	domain,	a	sequence	called	"SOCS	box"	in	the	C-terminal	domain	and	a	kinase-
Figure	16.	Representation	of	 JAK/STAT	molecular	pathway.	The	 interaction	 between	 receptor	 and	cytokines	results	in	the	formation	of	an	activated	receptor	complex.	This	complex	involves	JAK	that	cross-phosphorylates	 (A)	 and	phosphorylates	 the	 cytokine	 receptor	 (B).	 Subsequently,	 STAT	 is	 recruited	and	phosphorylated	by	JAK	(C).	Activated	STAT	dimerizes	and	then	translocates	to	the	nucleus	(D)	where	 it	can	 induce	 the	 transcription	of	 several	 genes	 (E),	 including	 those	 for	 STAT	 itself,	 SOCS	and	others	 that	regulate	cell	growth.	
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inhibitory	region	located	in	the	SH2	domain.	These	proteins	create	a	negative	feedback	 loop	 in	 JAK/STAT	axes66;	 the	activated	STAT,	 in	 fact,	promote	 the	transcription	 of	 SOCS	 genes	 and,	 once	 expressed,	 these	 proteins	 carry	 out	their	activities	in	three	different	ways:		1. binding	 to	 phospho-tyrosine	 receptors,	 thus	 physically	 blocking	 the	recruitment	of	STATs;	2. specifically	binding	JAKs	in	order	to	inhibit	its	kinase	activity;	3. interacting	with	 the	elongin	BC	complex,	 enabling	 the	ubiquitination	of	JAK	and	inducing	its	degradation	via	the	proteasome67.		The	 second	 class	 of	 negative	 regulators	 consists	 of	 the	 PIAS	 (PIAS1,	PIAS3,	PIASx	e	PIASy).	These	proteins	are	able	to	bind	STAT	activated	dimers	in	order	to	avoid	their	interaction	with	DNA.	Finally,	 among	 PTP	 the	 best	 known	 protein	 is	 SHP-1	 (Short	Heterodimer	 Partner-1),	 which	 contains	 two	 SH2	 domains	 and	 is	 able	 to	dephosphorylate	 JAK	 proteins	 or	 phosphorylated	 receptors	 to	 ease	 their	deactivation.			
3.1	Janus	family	kinase	(JAK)		 Various	 human	 malignancies	 are	 characterized	 by	 an	 excessive	activation	 of	 JAK	 and	 their	 associated	 transcription	 factors	 (STATs).	 There	are	 four	 JAKs:	 JAK1,	 JAK2,	 JAK3,	 and	TYK2.	 JAKs	molecular	weight	 is	 about	120-140	 kDa	 and	 it	 is	 composed	 from	 seven	 defined	 regions	 of	 homology	called	Janus	homology	domain	1	to	7	(JH1-7)	(Figure	17).	JH1	is	the	domain	containing	 the	 enzymatic	 activity	 and	with	 conserved	 Tyr	 fundamental	 for	JAK	 activation	 (e.g.	 Tyr	 1007/1008	 in	 JAK2).	 Phosphorylation	 of	 these	tyrosine	 residues	 leads	 to	 conformational	 changes	 in	 JAK	 protein	 thus	facilitating	 the	 binding	 of	 the	 substrate.	 JH2	 is	 a	 "pseudokinase	 domain",	 a	domain	 structurally	 similar	 to	 a	 tyrosine	 kinase	 and	 essential	 for	 a	 normal	kinase	 activity,	 but	 lacking	 enzymatic	 activity.	 JH3-JH4	 domains	 show	similarity	 with	 Src-homology-2	 (SH2)	 domains.	 JH4-JH7,	 at	 the	 N-terminal	
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domains,	 are	 called	 FERM	 domain,	 that	 is	 a	 protein	 module	 involved	 in	localising	proteins	to	the	plasma	membrane68.		
JAK	kinases,	 either	alone	or	 in	 combination	with	other	 JAKs,	may	be	preferentially	 activated	 depending	 on	 the	 receptor	 that	 is	 going	 to	 be	activated.	The	 JAK	 family	gets	active	when	 two	 JAKs	are	brought	 into	 close	proximity	and	the	trans-phosphorylation	is	allowed.	Once	activated,	JAKs	can	phosphorylate	additional	targets	which	include	both	the	receptors	and	their	major	substrates,	the	STATs.			 Activation	 of	 JAK-dependent	 intracellular	 signaling	 is	 regulated	 at	various	 levels.	 Conformational	 restraint	 of	 the	 JH1	 domain	 through	association	with	JH2	domain	maintains	the	kinase	in	an	inactive	form	prior	to	receptor	 engagement.	 Meanwhile,	 the	 action	 of	 tyrosine	 phosphatases	 and	the	 expression	of	 specific	 inhibitors	of	 JAKs	 limit	 the	duration	of	 JAK-STAT	signaling.		Among	 JAKs,	 JAK2	 has	 a	 key	 role	 in	 the	 activation	 of	 JAK/STAT	pathway	 due	 to	 its	 Tyr	 kinase	 activity.	 JAK2	 is	 tied	 to	 different	 cytokine	receptors;	the	binding	of	the	ligands	(e.g.	cytokines	such	as	IL-6,	IL-10,	etc.)	to	their	receptors	triggers	the	activation	of	JAK2	that,	in	turn,	phosphorylates	Tyr	 residues	 on	 the	 same	 receptor	 thus	 creating	 sites	 for	 interaction	 with	protein	containing	p-Tyr-binding	SH2	domains,	such	as	STAT369.	 			
3.2	Signal	transducer	and	activator	of	transcription	(STAT)		 Constitutive	 activation	 of	 STATs	 occurs	 at	 very	 high	 frequency	 in	different	 hematopoietic	 malignancies	 and	 solid	 tumors70.	 Among	 the	
Figure	17.	 JAK	structure.	A	 representation	of	 the	 domains	 that	 form	 JAK	 structure:	 JH1	 (kinase),	 JH2	(pseudokinase)	and	JH3-7	(FERM	domain).	The	phosphorylation	site	Tyr1007/1008	characterized	JAK2	isoform.	
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cytokines	 secreted	 by	 microenvironmental	 cells	 the	 most	 released	 is	interleukin-6	(IL-6)71.	STAT3	has	a	pivotal	role	 in	promoting	cell	survival	by	regulating	the	expression	 of	 anti-apoptotic	 proteins	 such	 as	 Mcl-1	 and	 Bcl-2,	 both	 over-expressed	in	CLL.	For	this	reason,	among	all	proteins	belonging	to	the	STAT	family,	 in	 this	 thesis	 we	 focused	 on	 STAT3,	 the	 main	 mediator	 of	 IL-6/JAK/STAT	pathway.		This	 signaling	 pathway,	 involved	 in	 the	 pathogenesis	 of	 many	 solid	and	 hematological	 tumors,	 starts	 with	 the	 binding	 of	 from	 the	 structural	point	of	view,	it	is	a	glycoprotein	of	184	amino	acids	composed	by	four	alpha	helices,	 with	 a	 molecular	 weight	 of	 22-28	 kDa,	 and	 encoded	 by	 a	 gene	localized	 in	 chromosome	 7.	 It	 was	 identified	 in	 1986	 and	 named	 B-cell	stimulatory	 factor	 2,	 because	 of	 its	 ability	 to	 stimulate	 activated	 B	 cells	 to	differentiate	into	plasma	cells	and	to	secrete	immunoglobulins.	Moreover,	IL-6	 has	 pleiotropic	 functions:	 it	 is	 not	 only	 an	 important	 regulator	 of	inflammatory	and	immune	responses,	but	also	of	metabolism,	hematopoiesis,	angiogenesis	and	bone	homeostasis.	IL-6	is	produced	by	different	cell	types,	including	 monocytes,	 B	 and	 T	 lymphocytes,	 fibroblasts,	 keratinocytes,	endothelial	cells,	adipocytes,	and	several	types	of	cancer	cells.			 The	 interaction	 between	 IL-6	 and	 its	 receptor	 is	 not	 sufficient	 to	activate	 signal	 transduction,	 but	 requires	 binding	 the	 of	 the	 IL-6/IL-6Rα	complex	 to	 the	 transducing	 subunit	 of	 the	 IL-6	 cytokines	 family,	 known	 as	gp130.	The	formation	of	the	IL-6/IL-6Rα/gp130	trimeric	complex	allow	the	recruitment	of	the	non-receptor	tyrosine	kinase	JAK2	and	of	STAT3	protein.	STAT3	 protein	 belongs	 to	 the	 STAT	 protein	 family,	 composed	 of	 7	members	STAT1,	2,	3,	4,	5a,	5b	and	6.	STATs	are	activated	by	all	the	members	of	the	IL-6	cytokines	family,	including:	IL-12,	IL-13,	interferons,	IL-10,	G-CSF	(Granulocyte-Colony	 Stimulating	 Factor)	 and	 other	 growth	 factors68.	 The	gene	encoding	this	protein	is	located	on	chromosome	17q21.31.		Two	 functionally	 distinct	 STAT3	 isoforms	 are	 known:	 STAT3α	(complete)	 and	 STAT3β	 (missing	 of	 TAD	 trans-activation	 domain	 at	 the	 C-terminal).		The	main	isoform,	STAT3α,	is	a	protein	of	770	amino	acids	formed	by	six	distinct	functional	domains	(Figure	18):	
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• a	N-terminal	domain;	
• a	leucine	zipper	coiled-coil	domain;	
• a	 DNA-binding	 domain	 (DBD)	 that	 allow	 STAT3	 to	 exert	 its	function	of	transcriptional	activator;	
• a	linker	domain;	
• a	 SH2	 domain	 (Src	 Homology	 2)	 essential	 for	 dimerization	 and	recruitment	 to	 the	 receptor;	 in	 this	 domain	 there	 is	 the	 tyrosine	705	which	is	phosphorylated	by	JAK2;	
• a	 C-terminal	 tail	 with	 a	 TAD	 trans-activation	 domain,	 whose	activity	is	stimulated	by	serine	727	phosphorylation.			 The	 beta	 isoform	 of	 STAT3,	 instead,	 is	 a	 protein	 truncated	 at	 amino	acid	715;	it	is	produced	by	alternative	splicing	in	correspondence	of	the	exon	23	and	deficits	the	SH2	domain.	
	 The	regulation	of	STAT3	activity	occurs	through	two	different	sites	of	phosphorylation:	 the	 tyrosine	 (Tyr)	 705	 and	 serine	 (Ser)	 727.	 STAT3	phosphorylation	 at	 Tyr705	 is	 due	 to	 JAK2	 kinase	 and	 regulates	 the	dimerization	 through	 the	 SH2	domain	 (which	 recognize	 phospho-Tyr).	 The	formation	 of	 STAT3	 homodimers	 or	 STAT3-STAT1	 heterodimers	 are	indispensable	for	the	activation	of	the	JAK/STAT	pathway;	in	fact,	only	in	the	dimeric	form,	STAT3	is	able	to	migrate	into	the	nucleus	where	it	binds	to	the	DNA	consensus	motifs	(DBD	region)	of	its	target	genes.		In	 addition	 to	 tyrosine	 phosphorylation,	 which	 is	 found	 to	 be	constitutively	 present	 constitutively	 in	 various	 solid	 and	 blood	 tumors,	STAT1,	 3,	 4,	 5a	 and	 5b	 are	 occasionally	 phosphorylated	 at	 Ser	 in	 the	 C-
Figure	18.	STAT3α	structure.	It	is	recognizable	the	N-terminal	domain,	the	coiled-coil	domain,	the	DNA	binding	 domain,	 the	 linker	 domain,	 the	 SH2	 domain	 and	 the	 trans-activation	 domain.	 The	 two	phosphorylation	sites	of	STAT3α,	Tyr	705	and	Ser727,	are	shown.	
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terminal	transactivation	domain.	The	role	of	STAT3	Ser727	phosphorylation	is	 still	 not	 defined:	 some	 studies	 suggest	 it	 has	 an	 important	 role	 in	transcriptional	 activity,	 while	 others	 demonstrate	 it	 plays	 an	 inhibitory	function.	 In	 CLL,	 STAT3	 is	 constitutively	 phosphorylated	 at	 Ser727	 with	respect	to	normal	B	lymphocytes72,	but	the	phosphorylation	status	at	Tyr705	is	still	unclear73.			
3.3	JAK/STAT	pathway	in	oncogenesis		 Considering	 the	 importance	 of	 JAK/STAT	 axis	 for	 neoplastic	 cell	survival,	 the	 investigation	 on	 this	 pathway	 and	 its	 regulation/inhibition	 is	crucial.	 Several	 studies	 have	 shown	 that	 the	 inappropriate	 activation	 	 of	JAK/STAT	signaling	contributes	in	a	direct	way	to	oncogenesis.	The	aberrant	activation	of	STAT	has	been	described	in	several	cancers	and	has	been	well	characterized	also	in	leukemias.	Several	mechanisms	involved	in	constitutive	STAT	activation	have	been	described	in	hematological	cancer74.	Among	this:	
• an	 increased	 production	 of	 cytokines	 and	 their	 receptors;	 it	 can	occur	either	in	an	autocrine	or	paracrine	way;	
• a	 decreased	 expression	 of	 SOCS	 proteins	 due	 to	 methylation	 of	their	promoter	sequence;	
• a	decrease	of	tyrosine	phosphatases;	
• mutations	 "gain	 of	 function"	 of	 the	 receptor.	 In	 hematological	disorders	 the	 most	 common	 mutations	 affect	 Receptor	 Tyrosine	Kinases	 (RTKs),	 whereas	 they	 are	 not	 frequently	 found	 in	 the	cytokine	receptors;	
• mutations	 "gain	 of	 function"	 of	 the	 kinases	 that	 phosphorylate	STAT:	a	point	mutation	in	JAK2	pseudo-kinase	domain,	responsible	for	 its	 constitutive	 activation,	 is	 frequently	 observed	 in	 cases	 of	polycythemia	 vera	 and	 in	 some	 myeloproliferative	 disorders.	Another	 example	 is	 the	 t(9:12),	 found	 in	 acute	 lymphocytic	leukemia	 (ALL),	 resulting	 in	 the	 fusion	 between	 JAK2	 and	 Ets	 (a	
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transcription	 factor),	 that	 becomes	 constitutively	 active	 after	dimerization;	
• oncogene	 activation	 by	 other	 proteins:	 the	 oncogenic	 fusion	protein	 BCR/ABL	 (known	 as	 Chromosome	 Philadelphia)	 derives	from	 t(9:22)	 and	 it	 is	 found	 in	 all	 cases	 of	 chronic	 myeloid	leukemia	 (CML)	 and	 in	 some	 cases	 of	 ALL.	 BCR/ABL	 has	 the	constitutive	kinase	activity	of	ABL	and	activates	multiple	signaling	pathways,	 including	 that	 involving	 STAT5:	 BCR/ABL	 forms	 a	complex	 with	 the	 protein	 Hck,	 belonging	 to	 the	 family	 of	 Src	kinases,	resulting	in	STAT5	activation.		 The	great	number	of	mechanisms	by	which	 the	STAT	oncogenes	 are	activated	 and	 the	 several	 hematological	 malignancies	 in	 which	 they	 are	deregulated,	suggest	the	importance	of	these	proteins	in	the	pathogenesis	of	various	 diseases.	 Furthermore,	 STATs	 represent	 the	 link	 between	 several	pathways,	 that	 once	 altered,	 cause	 the	 development	 of	 varius	 neoplasms75.		STAT3,	 in	 fact,	 connects	 the	 pathway	 triggered	 by	 the	 interaction	 between	the	 epidermal	 growth	 factor	 (EGF)	 and	 its	 receptor	 (EGFR)	 and	 the	phosphoinositol	3-kinase	(PI3K)	axis.	 In	multiform	glioblastoma,	EGF/EGFR	signaling	 promotes	 STAT3	 to	 binding	 DNA,	while	 PI3K	 pathway	 negatively	affects	it76.	Moreover,	the	activity	of	STAT3	is	negatively	regulated	by	RAS/MAP-kinase	(Mitogen	Activated	Protein)	axis.	The	constitutive	expression	of	MEK,	one	 of	 the	 activated	 kinases	 of	 the	 pathway,	 that	 in	 turn	 activates	 ERK	(extracellular	signal-regulated	kinase)	or	the	overexpression	of	ERK	in	itself,	inhibits	the	activation	of	STAT3	mediated	by	IL-6	in	CHO	and	HEK	29322	cell	lines.			
3.4	Activation	of	STAT	independently	of	JAK		 B	cell	receptor	(BCR)	is	fundamental	for	the	development	of	normal	B	cells	 and	 it	 is	 also	 involved	 in	 the	 progression	 of	 the	most	 common	 B	 cell	disorders,	such	as	follicular	lymphoma,	mantle	cell	lymphoma	and	CLL.	
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	 In	 CLL,	 after	 the	 binding	 with	 the	 antigen,	 BCR	 triggers	 several	signaling	 pathways	 in	 order	 to	modify	 gene	 expression	 and	 determine	 cell	destiny.	BCR	requires	the	recruitment	of	the	cytosolic	protein	tyrosine	kinase	(PTK)	to	trigger	the	signaling	pathway.			 Lyn,	 a	 member	 of	 SFK,	 plays	 a	 central	 role	 in	 the	 initiation	 of	 the	transduction	pathway	triggering	a	rapid	cascade	involving	other	kinases	and	second	messengers,	which	are	involved	in	B	cell	proliferation,	differentiation,	apoptosis,	migration	 and	 cell	 growth	 arrest.	Whereas	 JAK	 proteins	 are	 not	involved	 in	BCR	pathway,	activation	of	STAT	due	 to	 this	axis	has	 long	been	ignored.	 However,	 literature	 data	 shown	 that	 Src	 kinases	 can	 directly	phosphorylate	the	STATs,	independently	from	JAK;	this	pathway	is	called	no-JAK	 PTK–STAT	 axis.	 In	 fact,	 Lyn,	 stimulated	 after	 BCR	 antigen	 stimulation,	can	 in	 turn	 phosphorylate	 STAT3	 Tyr705	 activating	 it77.	 However,	 the	phosphorylation	of	STATs	mediated	by	Lyn	through	BCR	is	transient.	This	is	probably	due	to	Lyn's	dual	role	in	both	positive	and	inhibitory	regulation	of	BCR	signaling.	For	this	reason,	the	functional	consequences	of	Lyn-mediated	STATs	activation	may	result	in	a	different	set	of	genes	transcribed	than	more	sustained	activation	by	the	JAKs78.				 	
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AIM	OF	THE	STUDY		 In	 CLL	 several	 molecules	 released	 from	 the	 microenvironment	partners	 (e.g.	MSCs),	 signal	 through	 JAK-STAT	 pathways,	 thus	 favoring	 cell	survival70.		Constitutive	 activation	 of	 JAKs	 and	 STATs	 occurs	 at	 very	 high	frequency	in	different	hematopoietic	malignancies	and	solid	tumors.	Among	JAKs,	 JAK2	has	a	key	 role	 in	 the	activation	of	 JAK/STAT	pathway	due	 to	 its	tyrosine	(Tyr)	kinase	activity.	JAK2	is	tied	to	different	cytokine	receptors;	the	binding	of	the	ligand	(e.g.	IL-6)	to	its	receptors	triggers	the	activation	of	JAK2	that,	in	turn,	phosphorylates	Tyr	residues	on	the	same	receptor,	thus	creating	sites	 for	 interaction	 with	 protein	 containing	 p-Tyr-binding	 SH2	 domains,	such	as	STAT368.		STAT3	has	a	pivotal	role	 in	promoting	cell	survival	by	regulating	the	expression	 of	 anti-apoptotic	 proteins	 such	 as	 Mcl-1	 and	 Bcl-2,	 both	 over-expressed	in	CLL.	STAT3	is	constitutively	phosphorylated	at	serine	(Ser)	727	residue	in	CLL	cells73,	while	its	Tyr-phosphorylation	status	is	unclear.		During	 this	 PhD	 program	 we	 planned	 to	 further	 investigate	JAK2/STAT3	 axis	 and	 to	 study	 how	 this	 pathway	 interacts	 with	 BCR/Lyn	signaling.	To	this	purpose,	we	were	aimed	at	analysing:	
• STAT3	expression	and	activation	in	CLL	cells;	
• inhibition	of	JAK2/STAT3	pathway	on	B	CLL	cells	through	AG490	and	Stattic	treatment;	
• MSC	pro-survival	effect	on	CLL	B	cells	after	JAK2/STAT3	inhibition	by	AG490	and	Stattic;		
• JAK2/STAT3	pathway	after	Lyn	inhibition	by	Dasatinb;	
• molecules	 involved	 in	 the	 cross-talk	 between	 BCR/Lyn	 and	JAK2/STAT3	pathways.	The	 aim	 of	 this	 study	 was	 to	 better	 understand	 CLL	 pathogenic	JAK2/STAT3	pathway	with	the	ultimate	goal	of	developing	new	therapeutic	strategies	for	CLL	patients.			
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MATHERIALS	AND	METHODS		
1.	Patients			 Leukemic	B	cells	will	be	obtained	from	CLL	patients.	We	analyzed	76	CLL	 patients	 (49	 males	 and	 27	 females),	 aged	 between	 49	 and	 90	 years,	enrolled	 by	 the	 Hematology	 Division	 (chief	 Prof.	 G.	 Semenzato),	 Padua	University	School	of	Medicine.			 Clinical	 characteristics	 of	 patients	 are	 listed	 in	Table	 I.	 In	 particular,	for	 each	patient	we	 reported:	 the	number	 of	white	 blood	 cells	 (WBCs),	 the	percentage	 of	 lymphocytes,	 mutational	 status	 of	 IgVH	 genes	 and	 the	expression	of	ZAP-70.	All	neoplastic	B	cells	of	the	76	patients	examined	were	positive	for	CD5,	CD19	and	CD23	markers,	typically	co-expressed	in	CLL	and	those	of	16	subjects	were	also	CD38	positive.		 B	lymphocytes	obtained	from	peripheral	blood	of	23	healthy	subjects	were	used	as	normal	controls.		
Table	I.	Patients	enrolled	in	the	study	Patients	 76	Median	age,	years	(range)	 72	(49-90)	Male/Female	 49/27	WBCs	count,	x109/l	(range)	 49,789	(4.7-300)	Lymphocytes,	%	(range)	 74	(46-97)	Mutated*	 34	ZAP70-positive†	 25	CD38-positive‡	 16	
 
 
*	 Immunoglobulin	 heavy	 chain	 variable	 region	 (IgVH)	 mutational	 status:	 patients	 with	 <2%	 differences	from	 the	 most	 similar	 germline	 gene	 in	 both	 the	 expressed	 VH	 and	 VL	 genes	 were	 define	 unmutated;	mutated	cases	were	defined	as	those	in	which	the	CLL	cells	displayed	≥2%	differences	in	either	the		
†	Parameter	assessed	by	flow	cytometric	analysis	(ratiometric	method,	cut-off>	0.5);		
‡	Parameter	assessed	by	flow	cytometric	analysis	(cutoff>	30%);		The	cell	samples	were	analyzed	by	the	flow	cytometer	FACSCanto	A	(Becton	Dickinson;	Franklin	Lakes,	NJ)	and	data	obtained	were	processed	using	 the	 software	FACSDiva	 7.	 For	each	analysis	20.000	events	were	acquired. 
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2.	Isolation	of	B	lymphocytes	from	peripheral	blood		
2.1	Purification	of	B	lymphocytes				 B	 lymphocytes	were	 isolated	 from	 peripheral	 blood	 of	 CLL	 patients.	From	a	sample	of	heparinized	venous	blood,	peripheral	blood	mononuclear	cells	 (PBMCs)	 cells	 were	 obtained	 proceeding	 with	 a	 layering	 on	Ficoll/Hypaque	 (F/H)	 (Amersham	 Biosciences;	 San	 Francisco,	 CA).	 This	method	exploits	the	difference	of	density	of	mononuclear	cells	(lymphocytes	and	 monocytes)	 with	 respect	 to	 the	 other	 elements	 of	 the	 blood.	Mononuclear	cells,	which	have	lower	density,	focus	on	the	layer	of	F/H	while	the	red	blood	cells	and	granulocytes	are	collected	on	the	bottom	of	the	tube.	Considered	 the	high	WBC	 count	 in	CLL	patients,	 peripheral	 blood	was	 first	diluted	in	1:6	ratio	with	0.9%	sodium	chloride	(saline)	at	room	temperature,	gently	 agitated,	 and	 later	 layered	 slowly	 over	 F/H	 solution.	We	 proceeded	with	a	centrifugation	at	900g	for	20	min	at	20°C,	without	brake.	The	ring	of	mononuclear	 cells	 formed	 at	 F/H	 interface	was	 aspirated	 and	 subjected	 to	two	successive	washes	with	saline	by	centrifugation	at	400g	for	10	minutes	at	20°C	 (Figure	19).	The	pellet	was	 resuspended	 in	 an	adequate	amount	of	saline	and	the	cells	were	counted	in	a	Burker	chamber.	
					
Figure	 19.	 Isolation	 of	 mononuclear	 cells	 from	 peripheral	 blood	 by	 stratification	 on	
Ficoll/Hipaque.	 By	 centrifugation	 on	 F/H,	 mononuclear	 cells	 were	 isolated	 from	 peripheral	 blood.	Mononuclear	 cells	 and	 platelets	 were	 concentrated	 above	 the	 layer	 of	 F/H	 because	 they	 have	 lower	density;	on	the	contrary,	the	red	blood	cells	(RBCs)	and	granulocytes	(PMNs)	have	a	higher	density	than	the	F/H	and	collect	on	the	bottom	of	the	tube.	RT:	room	temperature.	
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2.2	Purification	of	B	lymphocytes	with	sheep	red	blood	cells	(SRBCs)			 In	most	of	CLL	cases,	 the	percentage	of	 leukemic	B	cells	was	greater	than	90%	of	PBMCs	(peripheral	blood	mononuclear	cells)	isolated.			 When	 the	 cell	 population	 had	more	 than	10%	of	 T	 lymphocytes,	we	further	performed	 the	purification	of	B	 lymphocytes	by	SRBC	method.	This	purification	allows	the	removal	of	T	cells	 from	the	other	mononuclear	cells,	taking	 advantage	 from	 their	 ability	 to	 bind	 and	 form	 complexes,	 called	"rosettes",	with	SRBCs.	The	latter,	 in	fact,	express	on	their	surface	a	specific	receptor	 for	 the	 T	 lymphocyte	 marker	 CD2;	 SRBCs	 treatment	 with	neuraminidase	make	more	accessible	the	receptor	to	CD2	binding.			 25x106	 aliquots	 of	 PBMCs	 were	 transferred	 into	 a	 10ml	 centrifuge	tube	 and	 1ml	 of	 SRBC	 treated	with	 neuraminidase	was	 added.	 PBMCs	 and	SRBCs	were	then	incubated	at	37°C	for	25	min,	centrifuged	at	4°C	for	10	min	at	200g	without	brake,	and	finally	subjected	to	a	new	incubation	at	4°C	for	30	min.	 The	 supernatant	 was	 then	 aspirated	 and	 culture	medium	 RPMI	 1640	(Invitrogen;	 Paisley,	 UK)	was	 added.	 The	mixture	was	 gently	 resuspended,	layered	over	F/H	solution,	and	centrifuged	at	4°C	for	20	min	at	900g	without	brake.	T	cells,	surrounded	by	SRBCs,	accumulated	to	the	bottom	of	the	tube,	having	 a	 density	 greater	 than	 F/H,	 while	 the	 non-T	 mononuclear	 cells	(monocytes	 and	 B	 cells)	 were	 concentrated	 above	 the	 F/H	 layer.	 The	interface	layer,	which	contains	B	cells,	was	transferred	into	a	10ml	tube.	Two	washes	with	 saline	were	performed	at	400g	at	20°C	 for	10	min	and,	 in	 the	end,	cells	were	resuspended	and	counted	in	a	Burker	chamber	(Figure	20).	
Figure	 20.	 Purification	 with	 SRBCs.	 When	 the	 mononuclear	 cells	 obtained	 by	 separation	 over	 F/H	contained	a	percentage	of	lymphocytes	T≥10%,	we	used	SRBCs	to	remove	them.	This	method	exploits	the	ability	of	T	 cells	 to	bind,	 through	 their	marker	CD2,	 to	SRBCs	 treated	with	neuraminidase	and	 forming	rosettes	that	are	removed	by	further	stratification	on	F/H.	
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2.3	Purification	of	B	lymphocytes	using	RosetteSep	kit			 We	used	the	RosetteSep	kit	(StemCell	Technologies;	Vancouver,	CND)	to	obtain	B	cells	from	whole	blood	of	normal	healthy	donors.	The	kit	consist	of	 a	 cocktail	 of	 antibodies	 directed	 against	 surface	 antigens	 expressed	 by	hematopoietic	cells	(CD2,	CD3,	CD16,	CD36,	CD56,	CD66b)	and	glycophorin	A	expressed	by	red	blood	cells.	This	mixture	of	antibodies	binds	 "not-B"	cells	and	 red	 blood	 cells	 creating	 immunerosettes.	 In	 this	 way,	 CD19+	 B	lymphocytes	were	isolated	from	whole	blood	by	negative	selection.	 		 Each	 ml	 of	 blood	 was	 incubated	 with	 50μl	 of	 RosetteSep	 at	 room	temperature	 for	 20	minutes.	 The	 samples	 were	 then	 diluted	 1:2	 with	 PBS	(Phosphate	 Buffered	 Saline)1X	 +	 2%	 FBS	 (Fetal	 Bovine	 Serum),	 gently	agitated,	and	then	 layered	over	F/H.	We	proceeded	with	a	centrifugation	at	900g	for	30	minutes	at	room	temperature,	followed	by	the	aspiration	of	the	ring	 formed	 at	 the	 F/H	 interface	 containing	 B	 cells.	 It	 was	 resuspended	 in	PBS1X	+	 2%	FBS	 and	 centrifuged	 at	 400g	 for	 10	minutes.	 Finally,	 the	 cells	were	resuspended	in	PBS1X	and	counted	in	a	Burker	chamber	(Figure	20).		
	
3.	Isolation	of	MSCs	from	bone	marrow	blood		Mesenchymal	stromal	cells	 (MSCs)	were	 isolated	 from	the	BM	blood	of	CLL	patients	and	healthy	subjects.	After	F/H	stratification,	BM	mononuclear	cells	(BMMCs)	 were	 plated	 and	 incubated	 at	 37°C	 in	 humidified	 atmosphere	containing	 5%	 CO2	 and	 allowed	 to	 attach	 for	 7	 days;	 the	 non-adherent	
Figure	20.	Purification	with	RosetteSep	kit.	CD19+	B	lymphocytes	were	isolated	from	whole	blood	of	healthy	donors	by	negative	selection.	10ml	of	venous	whole	blood	were	incubated	for	20	min	at	RT	with	500μl	 of	 RosetteSep.	 Afterwards,	 through	 stratification	 on	 F/H,	 we	 get	 the	 CD19+	 B	 cells,	 which	 are	concentrated	just	above	the	layer	of	F/H,	while	the	rest	of	the	cells	related	to	the	rosettes	were	collected	on	the	bottom	of	the	tube.	
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fraction	was	 discarded	 and	 adherent	 cells	maintained	 until	 confluence	 and	for	 further	 expansion.	 MSC	 phenotype	 was	 characterized	 through	 the	expression	of	CD14,	CD31,	CD34,	CD73,	CD90,	CD45,	and	CD105	markers.	The	capability	of	MSCs	to	differentiate	into	mesenchymal	lineages	(e.g.	adipocytes	and	osteocytes)	was	assessed	(Figure	21).		
		
4.	Cell	cultures	condition			 Aliquots	of	B	(CD19+/CD5+)	and	T	lymphocytes	(CD5+)	obtained	from	patients	 with	 CLL,	 normal	 B	 lymphocytes	 (CD19+)	 were	 cultured	 in	 RPMI	1640	medium	with	10%	FBS	and	antibiotics	at	a	concentration	of	2x106/ml	in	 24-	 or	 48-wells	 plates.	 Cells	 were	 incubated	 at	 37˚C	 in	 a	 humidified	atmosphere	 containing	5%	CO2	with	or	without	AG490	 (Selleck	Chemicals;	Munich,	Germany)	at	the	concentration	of	10,	30,	50	and	100µM	and	Stattic	(Selleck	Chemicals)	at	the	concentration	of	5,	7.5	and	10µM	for	24,	48	and	72	hours.	 For	 some	 experiments	we	have	 also	 used	 a	 SHP-1	 inhibitor,	 sodium	orthovanadate	 (Na3VO4)	 at	 the	 concentration	 of	 100	 μM	 (Sigma-Aldrich;	Milan,	Italy	),	and	Dasatinib	(Selleck	Chemicals)	at	the	dose	of	0.1µM.					
5.	B	CLL	cells/MSCs	co-culture			 Some	 experiments	 were	 performed	 on	 MSC	 layer.	 For	 co-culture	experiments,	2x105/well	MSCs	from	CLL	were	seeded	into	24	well	plates	and	incubated	before	 the	experiment	at	37˚C	 in	5%	CO2	up	to	confluence.	Then,	
Figure	 21.	 Different	 lineages	 from	 MSCs.	 A)	 Undifferentiated	 MSCs;	 B)	 MSCs	 differentiated	 into	adipocytes	-	Oil	red	stained;	C)	MSCs	differentiated	into	osteocytes	-	von	Kossa	stained.	
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CLL	cells	were	added	to	MSCs	layer	at	a	ratio	of	2,5:1.	Cells	were	then	treated	at	 the	 same	 condition	 of	 culture	 alone	 to	 evaluate	 a	 possible	 resistance	 to	drug	treatment	due	to	the	co-culture	with	MSCs.			
6.	Subcellular	Fractionation		 The	 subcellular	 fractionation	 is	 a	 technique	 that	 allows	 the	 study	 of	proteins	 in	different	cellular	compartments.	The	 fractions	 that	are	obtained	are	defined	"enrichment"	of	the	following	components:	cytoplasmic/soluble,	of	the	membrane,	microsomal,	mitochondrial	and	nuclear.	We	used	a	commercial	kit	(Thermo	Scientific,	Rockford,	IL,	USA)	using	detergents	 which	 could	 separate	 cytoplasmic,	 membrane	 and	 nuclear	proteins.		 107	 lymphocytes	 were	 centrifuged	 and	 incubated	 with	 different	buffers	 following	 manufacture’s	 protocol.	 The	 buffers	 are:	 Cytoplasmic	Extraction	Buffer	(CEB),	Membrane	Extraction	Buffer	(MEB)	and	the	Nuclear	Extraction	Buffer	(NEB)	with	the	add	of	phosphatase	and	protease	inhibitors.		
		
7.	Preparation	of	cell	lysates		 Cells	(5×105	for	each	assay)	were	prepared	by	cell	lyses	with79:	
• Tris(hydroxymethyl)aminomethane-hydrochloride	 (TRIS-HCl)	 pH	6.8	20	mM;	
Figure	 .	Representation	of	 cell	 fractionation	protocol.	Proteins	were	 collected	using	 several	buffers.	Cytoplasmic	 Extraction	 Buffer	 (CEB),	 Membrane	 Extraction	 Buffer	 (MEB)	 and	 the	 Nuclear	 Extraction	Buffer	(NEB).	
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• soidum	cloride	(NaCl)	150	mM;	
• Ethylenediaminetetraacetic	acid	(EDTA)	2	mM;	
• ethylene	glycol	tetraacetic	acid	(EGTA)	2	mM;	
• Triton	X-100	0.5%;		
• complete	 protease	 inhibitor	 cocktail	 (Roche;	 Mannheim,	Germany);		
• sodium	orthovanadate	1	mM	(Calbiochem;	Gibbstown,	NJ).	To	use	 these	 lysates	 for	 SDS-PAGE	 (polyacrylamide	 gel	 electrophoresis)	analysis,	the	follow	substance	were	added:	
• 10%	glycerol;	
• 2%	sodium	dodecyl	sulphate	(SDS);	
• 1%	β-mercaptoethanol;	
• Dye	(Pyronin)	(Sigma-Aldrich;	Milan,	IT).	Subsequently,	the	lysates	were	vortex,	boiled	at	of	100°C	for	5	minutes.			
8.	Polyacrylamide	gel	electrophoresis	in	SDS	(SDS-PAGE)		 The	polyacrylamide	gel	electrophoresis	 in	SDS	 is	one	of	 the	methods	used	to	separate	a	mixture	of	proteins	on	the	basis	of	their	molecular	weight.	SDS	 is	 a	 ionic	 detergent	 that	 binds	 tightly	 to	 proteins	 causing	 their	denaturation.	 In	 the	 presence	 of	 an	 excess	 of	 SDS,	 approximately	 1.4g	 of	detergent	will	bind	to	each	gram	of	protein,	providing	a	constant	amount	of	negative	charge	per	unit	mass.	Therefore,	during	electrophoresis,	all	protein-SDS	 complexes	move	 toward	 the	 anode,	 and	 thanks	 to	 the	molecular	 sieve	properties	 of	 the	 gel,	 their	 mobility	 is	 inversely	 proportional	 to	 their	molecular	weight.	By	the	migration	of	standard	proteins	of	known	molecular	weight	 simultaneously	 to	 samples,	 it	 is	 possible	 to	 determine	 the	 protein	sample	weights.		 SDS	 polyacrylamide	 gel	 is	 prepared	 following	 Laemmli	method.	 The	electrophoretic	plate	consists	of	two	types	of	gel:	
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• Stacking	gel	(Tris-HCl	0.5	M	at	pH	6.8),	which	allow	concentrates	the	protein	 samples	 so	 that	 they	 are	 all	 aligned	 at	 the	 start	 of	electrophoresis.	
• Running	gel	(Tris-HCl	1.5	M	at	pH	8.8),	in	which	the	real	separation	of	proteins	occurs.	The	 plate	 size	 of	 10×8cm	 is	 fixed	 in	 the	Hoefer	Mighty	 Small-If	 250	Scientific	Instruments	machine	(Amersham	Biosciences).	The	electrophoresis	was	run	for	about	2	hours	at	25mA.	
		
9.	Western	blotting		 The	 western	 blotting	 (WB)	 or	 immunoblotting	 is	 an	 immunoassay	able	 to	 detect	 traces	 of	 a	 specific	 protein	 in	 a	 heterogeneous	 mixture,	combining	 the	 high	 resolving	 power	 of	 gel	 electrophoresis	 with	 the	specificity	of	the	antibodies.	The	WB	is	a	technique	with	high	sensitivity,	able	to	detect	quantities	of	protein	in	the	order	of	nanograms.		 After	 SDS-PAGE,	 proteins	 are	 transferred	 onto	 a	 nitrocellulose	membrane	 by	 the	 action	 of	 an	 electric	 field,	 obtained	 by	 applying	 the	appropriate	current	of	350mA	for	2	hours	and	30	minutes.	The	buffer	used	for	 the	 transfer	consists	of:	25mM	Tris,	192mM	glycine,	20%	methanol	and	0.1%	 SDS	 with	 a	 final	 pH	 of	 8.0.	 After	 the	 transfer,	 the	 membrane	 is	 left	overnight	 in	 the	 saturation	 buffer	 consisting	 of	 50mM	 Tris-HCl,	 pH	 7.5,	150mM	 NaCl	 and	 5%	 bovine	 serum	 albumin	 (BSA),	 for	 nonspecific	 sites	saturation.	 Follows	 the	 incubation	 for	 2	 hours	 and	 30	 min	 at	 RT	 of	 the	primary	 Abs,	 diluted	 in	 “dilution	 buffer”	 (50mM	 Tris-HCl,	 pH	 7.5,	 150mM	NaCl,	1%	BSA).	For	 our	 study	 we	 used	 the	 following	 antibodies:	 anti-P-Tyr,	 which	recognizes	 proteins	 phosphorylated	 on	 tyrosine	 residues;	 anti-STAT3,	 anti-STAT3	Ser727,	anti-STAT3	Tyr705,	polyclonal	anti-Lyn,	anti-JAK2,	anti-JAK2	Tyr1007/1008	 (Cell	 Signaling	 Technology,	 Inc.;	 Danvers,	 MA);	 anti-Lyn	Tyr396	 (Epitomics	 Onc.;	 Burlingame,	 CA);	 anti-SHP-1,	 anti-SHP-1	 Ser591	(Millipore;	Billerica,	MA);	anti-α-tubulin	and	anti-β-actin	(Sigma-Aldrich).	 In	
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addition,	 for	 apoptosis	 study,	 we	 used	 an	 anti-PARP	 (Cell	 Signaling	Technology,	Inc.).		 Three	 washes	 of	 10	min,	 each	 at	 RT,	 were	 subsequently	 performed	using	 “washing	 buffer”	 (TRIS-HCl	 1M,	 NaCl	 3M,	 Tween20	 0.1%	 at	 pH	 7.5).	Membranes	were	 then	 incubated	 for	 30	minutes	with	 a	 secondary	 anti-IgG	Ab,	obtained	against	the	animal	species	 immunized	for	the	primary	Ab.	The	secondary	 Ab	 is	 conjugated	 with	 horseradish	 peroxidase	 (Amersham	International	 Biotechnology;	 Buckingamshire,	 UK)	 and	 diluted	 in	 “dilution	buffer”.	After	three	additional	washes	with	“washing	buffer”,	 the	membrane	was	 subjected	 to	 the	 detection	 antibody	 with	 the	 enhanced	ChemiLuminescence	system	(ECL)	(Pierce;	Rockford,	Illinois):	the	membrane	is	incubate	for	1	min	with	1ml	of	luminol	and	1	ml	of	H2O2,	which	in	contact	with	the	peroxidase	and,	as	a	result,	with	the	Ag-Ab	complex,	giving	rise	to	an	oxidation	 reaction	with	 light	 emission.	 The	membrane	was	 finally	 revealed	into	 the	 ImageQuant	LAS	500	(Amersham	Biosciences)	and	 the	bands	were	scanned	and	quantified	by	densitometry,	 using	 the	program	 ImageQuantTL	(Amersham	Biosciences),	supplied	with	the	instrument.			
10.	Flow	cytometry		 This	 technique	 allows	 a	 multiparametric	 evaluation	 of	 antigenic	characteristic	of	the	single	cells	by	the	analysis	of	visible	and	fluorescent	light	they	emit	when	flow	through	a	liquid	medium.		The	fluorochromes	used	in	this	thesis	were	fluorescein	isothiocyanate	(FITC),	which	 emits	 a	 fluorescence	 signal	 at	 530nm	 (green),	 phycoerythrin	(PE)	 emitting	 at	 585nm,	 tri-color	 (TC)	 that	 emits	 at	 667nm	when	 hit	 by	 a	monochromatic	 laser	 beam	 with	 λ	 equal	 to	 488nm,	 and	 finally,	 the	allophycocyanin	 (APC)	 that	 emits	 a	 fluorescence	 signal	 at	 690nm	 when	excited	by	a	laser	beam	with	λ	of	635nm.	The	cell	samples	were	analyzed	by	the	flow	cytometer	FACSCanto	A	(Becton	Dickinson;	Franklin	Lakes,	NJ)	and	data	obtained	were	processed	using	the	FACSDiva	7	software.		
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10.1	Immunophenotypic	analysis			 The	 immunophenotypic	 analysis	 on	 lymphocytes	 obtained	 from	peripheral	blood	of	CLL	patients	was	performed	through	flow	cytometry.	All	patients	express	the	typical	phenotypic	profile	according	to	standard	criteria	for	CLL	diagnosis11.	The	immunophenotyping	is	based	on	the	identification	of	surface	and	intracellular	Ag	using	mAb	conjugated	with	fluorochromes.	The	presence	of	a	certain	Ag	is	revealed	and	used	as	an	indicator	of	belonging	to	a	cell	 line	as	well	 as	 its	 level	 of	 maturation.	 For	 apoptosis	 analysis	 20.000	 events	 were	acquired.	
		
10.2	Apoptosis	analysis				 Apoptosis	 of	 different	 cell	 samples	 (pathological	 and	 normal	 B	lymphocytes	 and	 MSCs)	 was	 assessed	 using	 the	 Annexin	 V	 Apoptosis	Detection	Kit	(Immunostep,	Salamanca,	Spain).			 During	the	early	stages	of	apoptosis	the	plasma	membrane	undergoes	profound	changes	that	indicate	the	status	of	apoptotic	cells	to	macrophages,	which	ensure	 its	 elimination.	Phosphatidylserine	 (PS),	 a	negatively	 charged	aminophospholipid	normally	expressed	only	on	the	inner	side	of	the	plasma	membrane,	is	exposed	on	the	outer	surface.	The	Annexin	V	is	a	protein	that,	in	 the	 presence	 of	 high	 concentrations	 of	 Ca2+,	 recognizes	 and	 binds	selectively	the	PS,	making	it	useful	for	the	identification	of	apoptotic	cells	that	expose	 the	 phospholipid	 on	 their	 surface.	 Aliquots	 of	 250x103	 cells	 were	harvested,	 washed,	 and	 incubated	 for	 10	 min	 in	 the	 dark	 and	 at	 RT	 with:	100µl	 of	 binding	 buffer,	 a	 Ca2+-rich	 solution	 that	 optimizes	 the	 binding	 of	Annexin	V	to	the	PS,	5μl	of	Annexin	V	(FITC),	and	5µl	of	Propidium	iodide	PI,	PE),	 provided	 by	 the	 kit	 (1μl/ml	 final	 concentration).	 After	 the	 incubation,	100µl	of	binding	buffer	were	added	and	cells	were	analyzed	(Figure	22).		For	 each	 sample	 20.000	 events	 were	 acquired	 and	 the	 number	 of	apoptotic	cells	was	expressed	as	percentage	of	Annexin	V	positive	cells	in	the	total	cells	analyzed.		
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10.3	Phospho-protein	analysis			 Cells	(2x106	for	each	assay)	were	collected	after	15	min	and	24h	and	stained	 with	 anti-STAT3	 Tyr705	 PE	 (BD	 Biosciences),	 anti-STAT3	 Ser727	FITC	 (BD	 Biosciences),	 anti-JAK2	 Tyr1007/1008	 FITC	 (Abcam,	 Cambridge,	UK)	and	anti-CD19	APC	(BD	Biosciences)	monoclonal	antibodies.	Cells	were	stained	 with	 surface	 antibody	 anti-CD19	 for	 10	 minutes	 at	 room	temperature.	 Therefore,	 cells	 were	 washed,	 fixed	 and	 permeabilized	following	 the	 manufacture’s	 instructions	 and	 incubated	 with	 saturating	concentrations	 of	 the	 appropriate	 antibodies	 (anti-STAT3	 Tyr705,	 anti-STAT3	 Ser727	 and	 anti-JAK2	 Tyr1007/1008)	 for	 30	 minutes	 at	 room	temperature.	 After	 another	 wash,	 30.000	 total	 events	 were	 acquired	 and	samples	were	 gated	 on	 intact	 cells	 by	 forward	 scatter	 (FSC)	 vs	side	 scatter	(SSC).	For	analysis,	a	second	gating	step	on	CD19+	cells	was	used.	To	evaluate	the	quantity	of	phosphorylated	protein,	we	used	the	difference	between	the	Mean	 Fluorescence	 Intensity	 (MFI)	 of	 fully-stained	 samples	 and	 the	Fluorescence	Minus	One	(FMO)	controls.			
Figure	22.	A	representative	cytogram	of	Annex	V/IP	Test.		
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11.	Confocal	microscopy	analysis		 Aliquotes	 of	 the	 different	 cell	 samples	 (pathological	 and	 normal	 B	lymphocytes	 from	CLL)	were	collected,	washed	and	plated	on	poly-L-lysine	coated	 slides	 for	15	min	at	 room	 temperature.	Cells	were	 then	 fixed	 in	4%	paraformaldehyde	for	10	min,	washed	twice	with	PBS	1X	and	permeabilized	with	 0,1%	 Triton	 X-100	 (Sigma-Aldrich)	 for	 4	 min.	 Before	 staining,	 non-specific	protein	binding	was	blocked	by	incubating	the	slides	for	at	 least	30	min	 in	 2%	 bovine	 serum	 albumin.	 Cells	were	 then	 stained	with	 antibodies	against:	 Lamin	 B	 (Santa	 Cruz),	 STAT3	 and	 STAT3	 Tyr705	 (Cell	 Signaling)	diluited	 1:250,	 washed	 three	 times	 with	 PBS	 1X	 and	 than	 incubated	 with	secondary	 antibody	 for	 30	 minutes	 in	 the	 dark.	 The	 secondary	 antibodies	used	 are:	 anti-mouse-Alexa488	 (STAT3	 and	 STAT3	 Tyr705)	 and	 anti-goat-Alexa594	 (Lamin	 B).	 Then	were	 performed	 other	 three	washes	 in	 PBS	 1X.	Slides	were	mounted	with	 cover	 slips	 and	 fluorescence	was	detected	using	the	 UltraView	 LCI	 confocal	 system	 (Perkin	 Elmer;	 Walthaw,	 MA,	 USA)	equipped	with	a	fluorescence	filter	set	for	excitation	at	488	and	594	nm.	 			
12.	Statistical	analysis			 Statistical	 analysis	 was	 performed	 using	 Student's	 t	 test,	 paired	Student's	 t	 test,	 Fisher’s	 exact	 test,	 Wilcoxon	 matched	 pairs	 test	 and	Pearson’s	 test.	 Data	 are	 reported	 as	 mean	 ±	 standard	 deviation	 (SD)	 and	were	considered	statistically	significant	when	p	values	were	<0.05	or	less.		 	
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RESULTS			
1.	STAT3	is	over-expressed	in	CLL	B	cells		The	aberrant	 activation	of	 STATs	has	been	observed	 in	 solid	 tumors	and	 leukemias,	 and	 different	 mechanisms	 involved	 in	 STAT	 constitutive	activation	have	been	described,	the	over-expression	of	STATs74	included.		With	this	as	a	background,	by	western	blotting	analysis,	we	analyzed	the	 levels	 of	 STAT3	 protein	 in	 freshly	 isolated	 neoplastic	 B	 cells	 obtained	from	 76	 untreated	 CLL	 patients	 and	 in	 normal	 B	 lymphocytes	 from	 23	healthy	subjects.	A	significant	difference	in	STAT3	expression	was	observed	in	malignant	(1.28±0.13)	versus	normal	B	lymphocytes	(0.61±0.09;	Student’s	
t	test,	p<0.001)	(Figure	23).		
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Figure	23.	Expression	of	STAT3	protein	in	normal	and	CLL	B	cells.	A.	Densitometry	of	STAT3/β-actin	ratio	of	normal	subject	(n=23)	vs	CLL	patients	(n=54),	(Student’s	t	 test,	p<0.001).	B.	The	figure	shows	a	representative	blot	for	3	normal	controls	and	5	CLL	patients.	STAT3	expression	is	higher	in	CLL	samples	with	respect	to	donors.	
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2.	 STAT3	 is	 constitutively	 phosphorylated	 at	 Ser727	 and	
Tyr705	in	CLL	B	cells		The	 classical	 JAK2/STAT3	 pathway	 includes	 a	 cytokine/receptor	binding	 with	 JAK2	 recruitment	 at	 the	 receptor	 and	 its	 consequent	phosphorylation.	 Successively,	 p-JAK2	 phosphorylates	 STAT3	 Tyr705,	 thus	prone	 to	be	phosphorylated	at	Ser727	residue	by	serine	kinases,	 leading	 to	STAT3	dimerization	and	translocation	into	the	nucleus.		In	 normal	 B	 cells,	 very	 low	 levels	 of	 STAT3	 phosphorylation	 are	detected	at	basal	conditions.	As	regards	CLL,	by	flow	cytometry	and	western	blot,	 we	 firstly	 confirmed	 the	 known	 constitutive	 phosphorylation	 at	Ser72772,80	(Figure	24).		
	Although	 STAT3	 Ser727	 phosphorylation	was	 higher	 in	 CLL,	we	 did	not	observe	any	significant	difference	compared	with	normal	B	lymphocytes	
B	
A	
Figure	 24.	 Evaluation	 of	 STAT3	 phosphorylation	 at	 Ser727.	 A.	 Flow	 cytometry	 analysis	 of	 STAT3	phosphorylation	 at	 Ser727.	 Difference	 between	 normal	 (N=6)	 and	 CLL	 (N=27)	 is	 not	 significant	(Student’s	t	 test,	p=ns).	MFI=	Median	Fluorescence	Intensity.	 	B.	The	figure	shows	a	representative	blot	from	 3	 normal	 controls	 and	 5	 CLL	 patients.	 STAT3	 Ser727/STAT3	 ratio	 is	 not	 significantly	 different	between	normal	and	leukemic	B	cells.		
kDa 
80 
80 
STAT3	Ser727 
β-actin 43 
STAT3 
CLL Normal	
	 65	
(MFI:	 Normal	 cells,	 N=6:	 178.8±46.2	 vs	 CLL	 cells,	 N=27:	 334.6±109.6;	Student’s	t	test,	p=ns.	Figure	24	A).		As	far	as	STAT3	phosphorylation	at	Tyr705	is	concerned,	an	essential	step	 for	STAT3	activation,	by	 flow	cytometry	and	western	blot	analysis,	we	demonstrated	a	constitutive	phosphorylation	 in	CLL	cells,	although	 in	some	patients	 STAT3	 Tyr705	 phosphorylation	 is	 barely	 detected	 (MFI:	 Normal	cells,	 N=6:	 46.50±6.12	 vs	 CLL	 cells,	 N=25:	 211.3±35.85;	 Student’s	 t	 test,	p<0.05.	Figure	25).			
	We	 found	 a	 positive	 correlation	 between	 STAT3	 Ser727	 and	 STAT3	Tyr705	 phosphorylation	 in	 23	 patients	 analysed	 by	 flow	 cytometry	(Pearson’s	 test,	 p<0.0001),	 accounting	 for	 the	 sequential	 nature	 of	 STAT3	Ser-phosphorylation	to	STAT3	Tyr-phosphorylation	(Figure	26).			
 
A	
B	
Figure	25.	Evaluation	of	STAT3	phosphorylation	at	Tyr705.	A.	Flow	cytometry	evaluation	of	STAT3	phosphorylation	at	Tyr705.	Difference	between	normal	(N=6)	and	CLL	(N=25)	is	significant	(Student’s	t	test,	 p<0.05).	 MFI=	 Median	 Fluorescence	 Intensity.	 B.	 The	 figure	 shows	 a	 representative	 blot	 from	 2	normal	controls	and	6	CLL	patients.	Normal	B	cell	have	 less	STAT3	Tyr705	then	B	CLL	cells.	Neoplastic	cells	show	a	heterogenous	expression	pattern.	
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3.	STAT3	Tyr705	is	present	in	the	nucleus	of	CLL	B	cells		 STAT3	 Tyr705	 localization	 was	 analysed	 in	 normal	 and	 leukemic	 B	cells.	 To	 this	 purpose,	 by	 a	 subcellular	 protein	 fractionation,	 we	 separated	nuclei	 from	 cytosols	 of	 cells,	 detecting	 STAT3	Tyr705	 both	 in	 the	 cytosolic	and	 in	 the	 nuclear	 fractions	 of	 CLL	 B	 cells	 (Figure	 27A).	 The	 purity	 of	 the	different	subcellular	fractions	was	assessed	through	the	presence	or	absence	of	 PARP	 and	 α-Tubulin	 proteins,	 localized	 in	 nucleus	 and	 cytosol,	respectively.	These	 data	 were	 supported	 by	 confocal	 microscopy	 evaluation	 that	highlighted	 the	 presence	 of	 STAT3	 Tyr705	 at	 basal	 conditions	 both	 in	 the	nucleus	and	in	the	cytosol	of	leukemic	B	cells	(Figure	27B).	In	normal	B	cells	phosphorylated	STAT3	is	less	detectable	with	respect	to	neoplastic	B	cells.	The	presence,	at	basal	conditions,	of	STAT3	phosphorylated	at	Tyr705	in	the	nucleus	of	leukemic,	but	not	of	normal,	B	cells	may	be	a	consequence	of	the	constitutive	activation	of	STAT3	pathway	in	these	cells.	
	
	
	
	
Figure	 26.	 Correlation	 between	 STAT3	 Tyr705	 and	 STAT3	 Ser727.	 Figure	 shows	 the	 correlation	between	STAT3	Tyr705	and	STAT3	Ser727	 in	23	CLL	patients	 (Pearson’s	 test,	 p<0.0001).	MFI:	Median	Fluorescence	Intensity.	
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Figure	 27.	 STAT3	 subcellular	 localization.	 A.	 The	 membrane	 was	 immunostained	 with	 the	 anti-STAT3	Tyr705,	 anti-STAT3,	 anti-PARP	 and	 anti-α-Tubulin	 antibodies.	 PARP	 and	 α-Tubulin	 proteins	 were	 used	 to	assess	 the	 purity	 of	 nuclear	 and	 cytosolic	 fractions,	 respectively.	 STAT3	 Tyr705	 shows	 a	 strong	 nuclear	localization.	PARP	 fl:	 full	 length	PARP.	PARP	 cl:	 cleaved	PARP.	B.	 Confocal	microscopy	analysis	of	 STAT3	and	STAT3	Tyr705	 (Alexa	 488,	 green)	 in	normal	 and	CLL	B	 cells	obtained	 from	 peripheral	blood.	Lamin	B	 (Alexa	594,	red)	was	used	to	delimit	the	nucleus.	Both	STAT3	and	STAT3	Tyr705	are	localized	in	the	nucleus.	
A	
B	
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4.	Leukemic	microenvironment	sustains	STAT3	activation		 Considering	 the	 importance	 of	 bone	 marrow	 environment	 in	activating	 JAK/STAT	 pathways	 in	 CLL,	 by	 western	 blotting	 we	 evaluated	STAT3	phosphorylation	at	Tyr705	in	different	conditions:		1. freshly	isolated	CLL	B	cells;	2. CLL	B	cells	cultured	in	medium	alone	for	24h;		3. CLL	B	cells	cultured	for	24h	on	a	 layer	of	mesenchymal	stromal	cells	(MSCs).		We	showed	that	the	constitutive	phosphorylation	of	STAT3	at	Tyr705	observed	 in	 freshly	 isolated	B	 cells	 increased	when	cells	were	 cultivated	 in	medium	 alone	 and	 reached	 even	 higher	 values	 when	 CLL	 B	 cells	 were	cultured	 in	 presence	 of	 MSCs	 (Alone	 T=0:	 0.34±0.06	 vs	 Alone	 T=24h:	0.76±0.17;	 Wilcoxon	 matched	 pairs	 test,	 p<0.05	 and	 Alone	 T=0	 vs	 +MSCs	T=24h:	1.68±0.15;	Wilcoxon	matched	pairs	test,	p<0.01)	(Figure	28).		
Figure	 28.	 Modulation	 of	 STAT3	 Tyr705.	 	 A.	 A	 significant	 difference	 in	 STAT3	 phosphorylation	 at	Tyr705	was	demonstrated.	The	graph	reports	the	densitometric	analysis	of	STAT3	Tyr705/STAT3	ratio	of	7	samples.	(Alone	T=0	vs	Alone	T=24h;	Wilcoxon	matched	pairs	test,	p<0.05	and	Alone	T=0	vs	+MSCs	T=24;	 Wilcoxon	 matched	 pairs	 test,	 p<0.01).	 B.	 A	 representative	 western	 blot.	 MSCs:	 Mesenchymal	Stromal	Cells.	
A	
B	
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Interleukin-6	(IL-6)	is	the	principal	activator	of	JAK2/STAT3	signaling	and	 one	 of	 the	 most	 abundant	 cytokine	 released	 in	 the	 leukemic	microenvironment71.	We	analysed	JAK2/STAT3	pathway	activation	in	CLL	B	cells	after	IL-6	stimulation	(Figure	29).		
		
Figure	29.	Modulation	of	STAT3	Tyr705	phosphorylation	by	IL-6.	A.	Comparison	of	 STAT3	Tyr705	between	B	CLL	 cells	 alone	and	 treated	with	 IL-6	by	 flow	cytometry	 (N=8;	Wilcoxon	 test,	 p<0.01).	MFI:	Median	Fluorescence	Intensity.	IL-6:	Interleukin-6.	B.	STAT3	Tyr705	expression	pattern	after	15	minutes	and	24h	with(+)	or	without(-)	MSCs	and	IL-6.	STAT3	Tyr705	level	 is	approximately	the	same	in	B	cells	stimulated	with	IL-6	or	MSCs.	MSCs:	Mesenchymal	Stromal	Cells.	C.	Densitometry	of	western	blot	of	panel	B. 
A	
B	
C	
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As	 shown	 in	 Figure	 29	 A,	 by	 flow	 cytometry	 we	 demonstrated	 a	significant	 increase	of	phosphorylation	at	Tyr705	 in	 response	 to	 IL-6	 (N=8,	Wilcoxon	 test,	 p<0.01).	 The	 data	 obtained	 by	 WB	 showed	 that	 IL-6	 up-regulates	 STAT3	 Tyr705	 phosphorylation	 at	 levels	 comparable	 to	 those	obtained	when	CLL	cells	are	cultured	on	a	stromal	layer	(Figure	29	B).				
5.	Inhibition	of	JAK2/STAT3	induces	apoptosis	of	CLL	B	cells		 We	demonstrate	 the	constitutive	phosphorylation	of	STAT3	 in	CLL	B	cells.	 AG490	 is	 a	 specific	 inhibitor	 of	 JAK2	 protein	 that,	 in	 turn,	 is	 an	established	 activator	 of	 STAT3,	 through	 phosphorylation	 at	 Tyr70581.	 We	treated	 neoplastic	 B	 cells	with	 AG490	 to	 inhibit	 JAK2/STAT3	 axis.	We	 also	treated	 neoplastic	 B	 cells	 with	 Stattic,	 a	 non	 peptidic	 small	 molecule	 that	strongly	 inhibits	 STAT3	 activation,	 probably	 avoiding	 STAT3	 nuclear	translocation82.		B	 cells	 from	 CLL	 patients	were	 cultured	 alone	 or	 in	 the	 presence	 of	different	concentration	of	AG490	(10,	50	and	100μM)	or	Stattic	 (5,	7.5,	and	10μM),	and	assessed	for	cell	viability	after	24,	48	and	72	hours	(Figure	30).	The	same	experiments	were	performed	in	presence	of	MSCs	recovered	from	CLL	patients,	representing	tumor	microenvironment	and	strongly	supporting	neoplastic	B	cells	survival.		We	 demonstrated	 that	 both	 AG490	 and	 Stattic	 were	 able	 to	 induce	apoptosis	 in	 CLL	 cells	 in	 a	 dose-dependent	 manner,	 as	 shown	 by	 Annexin	V/PI	 tests	 and	 the	 presence	 of	 the	 cleaved	 form	 of	 PARP;	 in	 particular,	treatment	with	AG490	 (Figure	30	A	and	B)	and	Stattic	 (Figure	30	C	and	D)	were	able	to	bypass	environment	protection.							
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	By	Student’s	t	test	statistical	analysis,	we	found	a	significant	difference	in	cells	viability	between	untreated	and	treated	conditions	as	follows:		
• AG490:	24h,	N=8,	CLL	B	cells	alone	vs	+AG490	50µM	(62.90±4.24%	vs	38.30±7.22%,	 p<0.01),	 CLL	 B	 cells	 alone	 vs	 +AG490	 100µM	(62.90±4.24%	vs	21.50±4.50%,	p<0.001);	48h,	N=8,	CLL	B	cells	alone	vs	+AG490	 50µM	 (59.70±6.03%	 vs	23.00±3.00%,	 p<0.0001),	 CLL	 B	 cells	
Figure	 30.	 Inhibition	 of	 JAK2/STAT3	 pathway	 by	 AG490	 and	 Stattic.	 A.	 Evaluation	 of	 CLL	 B	 cells	viability	by	flow	cytometry,	after	AG490	(0,	10,	50,	100µM)	treatment	by	Annexin	V	(FITC)/PI	(PE)	test	with	(light	grey	histograms)	or	without	(black	histograms)	MSCs	at	the	time	points	of	24,	48	and	72h.	B.		Evaluation	of	CLL	B	cells	viability	and	phosphorylation	by	western	blot,	after	AG490	(0,	10,	50,	100µM)	treatment	 with/without	 MSCs	 at	 the	 time	 points	 of	 24,	 48	 and	 72h.	 Representative	 western	 blots	detected	 sequentially	 with	 the	 anti-STAT3	 Tyr705,	 anti-STAT3,	 PARP	 and	 anti-β-actin	 antibodies.	 C.	Evaluation	of	CLL	B	cells	viability	by	flow	cytometry,	after	Stattic	(0,	5,	7.5,	10µM)	treatment	by	Annexin	V	(FITC)/PI	(PE)	test	with	(light	grey	histograms)	or	without	(black	histograms)	MSCs	at	the	time	of	24,	48	and	72h.		D.	Evaluation	of	CLL	B	cells	viability	and	phosphorylation	by	western	blot,	after	Stattic	(0,	5,	7.5,	 10µM)	 treatment	with/without	MSCs	 at	 the	 time	 of	 24,	 48	 and	 72h.	 Representative	western	 blots	detected	sequentially	with	the	anti-STAT3	Tyr705,	anti-STAT3,	PARP	and	anti-β-actin	antibodies.	MSCs:	Mesenchymal	Stromal	Cells.	
A	
B	
C	
D	
	 72	
alone	 vs	+AG490	 100µM	 (59.70±6.03%	 vs	14.50±0.50%,	 p<0.00001);	72h,	 N=8,	 CLL	 B	 cells	 alone	 vs	 +AG490	 50µM	 (54.50±6.64%	 vs	11.60±5.14%,	 p<0.001),	 CLL	 B	 cells	 alone	 vs	 +AG490	 100µM	(54.50±6.64%	vs	16.50±2.50%	%,	p<0.0001).		These	results	indicate	that	AG490	is	able	to	induce	apoptosis	in	a	dose-dependent	manner.	
• AG490+MSCs:	 48h,	 N=4,	 CLL	 B	 cells	 alone	 vs	 +AG490	 100µM	(66.80±6.28%	vs	22.50±7.50%,	p<0.01);	72h,	N=4,	CLL	B	cells	alone	vs	+AG490	 50µM	 (68.10±7.63%	 vs	11.60±5.14%,	 p<0.001),	 CLL	 B	 cells	alone	vs	+AG490	100µM	(68.10±7.63%	vs	22.50±7.50%,	p<0.01).		These	data	show	that	AG490	is	able	to	bypass	environment	protection.		
• Stattic:	24h,	N=13,	CLL	B	cells	alone	vs	+Stattic	10µM	(60.96±3.91%	vs	31.78±4.31%,	p<0.0001),	48h,	N=13,	CLL	B	cells	alone	vs	+Stattic	10µM	(57.15±4.95%	vs	26.25±5.45%,	p<0.001);	72h,	N=13,	CLL	B	cells	alone	
vs	+Stattic	10µM	(61.63±5.25%	vs	25.29±6.64%,	p<0.001).		Stattic	affects	CLL	B	cells	viability	in	a	dose-dependent	manner.	
• Stattic+MSCs:	 24h,	 N=9,	 CLL	 B	 cells	 alone	 vs	 +Stattic	 10µM	(65.57±3.14%	vs	49.20±5.56%,	p<0.01);	48h,	N=9,	CLL	B	cells	alone	vs	+Stattic	10µM	(64.70±3.66%	vs	44.12±5.73%,	p<0.01);	72h,	N=9	CLL	B	cells	alone	vs	+Stattic	10µM	(64.91±4.43%	vs	44.90±7.85%,	p<0.01).	MSCs	 are	 unable	 to	 protect	 neoplastic	 cells	 from	 Stattic-induced	apoptosis.			
6.	Crosstalk	between	JAK2/STAT3	and	BCR/Lyn	axes	in	CLL	B	
cells		
6.1	AG490	inhibits	both	Lyn	and	SHP-1	in	CLL	B	cells			 Lyn	 is	 the	 tyrosine	kinase	 that	 initiates	 the	phosphorylation	 cascade	triggered	 by	 the	 B	 Cell	 Receptor	 (BCR)-Antigen	 interaction.	 Activated	 Lyn	phosphorylates	proteins	 that	work	 as	 inhibitors	of	 the	BCR,	 such	as	 SHP-1,	which	 acts	 as	 phosphatase	 for	 several	 substrates,	 thus	 switching	 off	 BCR	
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signaling.	 Lyn	 itself	 is	 one	 of	 SHP-1	 target	 proteins	 and,	 once	dephosphorylated,	becomes	inactive.		Recent	data	on	chronic	myeloid	leukemia	(CML)	suggest	a	connection	between	JAK2	and	SHP-1.	This	relationship	is	still	unclear,	but	Samanta	K	et	
al.	showed	that	AG490	inhibits	Lyn	through	SET-PP2A-SHP-1	pathway83.	Neoplastic	 B	 cells	 from	 9	 CLL	 patients	 were	 cultured	 alone	 or	 in	presence	 of	 different	 concentrations	 of	 AG490	 (10,	 50	 and	 100μM)	 and	Stattic	 (5,	 7.5,	 10μM).	 By	 western	 blotting,	 the	 expression	 and	phosphorylation	status	of	SHP-1	and	Lyn	were	assessed.		The	 treatment	with	 AG490	 inhibited	 the	 phosphorylation	 of	 SHP-1	 at	Ser591,	 activating	 the	 phosphatase.	 SHP-1	 activation	 leads	 to	 Lyn	 Tyr396	dephosphorylation/inactivation.	 Particularly,	 after	 treatment	 with	 AG490,	we	observed	a	decrease	 in	SHP-1	Ser591	and	Lyn	Tyr396	phosphorylation,	while	total	protein	levels	remained	unaffected.		As	 expected,	 the	 treatment	 with	 Stattic	 did	 not	 affect	 Lyn	 and	 SHP-1	phosphorylation	 since	 this	 inhibitor	 acts	 downstream,	 mainly	 inhibiting	STAT3	homodimers	binding	to	DNA	(Figure	31).		
Figure	31.	Lyn	Tyr396	and	SHP-1	Ser591	assessment	after	inhibition	with	AG490	and	Stattic.	CLL	B	 cells	were	 cultivated	 for	24h	with	AG490	 (0,	10,	50,	 100µM)	or	Stattic	 (0,	 5,	 7.5,	10µM)	and	 protein	expression	pattern	evaluated	by	western	blotting.	AG490	inhibits	STAT3	Tyr705,	SHP-1	Ser591	and	Lyn	Tyr	396	phosphorylation,	but	Stattic	only	affect	STAT3	Tyr705	activation.	
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To	 confirm	 the	 link	 between	 JAK2	 inhibition	 by	 AG490	 and	 Lyn	dephosphorylation,	 we	 added	 sodium	 orthovanadate	 (Na3VO4,	 100	 μM),	 a	phosphatase	 inhibitor,	 to	 cell	 culture	 to	 restore	 Lyn	 activation	 (resulting	from	 the	 inactivation	 of	 SHP-1	 phosphatase.	 As	 shown	 in	 Figure	 32,	 Lyn	Tyr396	phosphorylation	was	restored.		
	
6.2	Lyn	inhibition	by	Dasatinib	induces	STAT3	inactivation			Wang	 L	 et	al.77	previously	demonstrated	 that	 a	 phosphorylation	 and	activation	 of	 STAT,	 independent	 from	 JAK,	 was	 possible	 through	 BCR/Lyn	axis.	The	Src-family	kinase	inhibitor	Dasatinib	inhibits	Lyn	at	Tyr396	residue,	thus	restoring	apoptosis	of	CLL	B	cells84.	We	 treated	 leukemic	 B	 cells	 with	 Dasatinib	 (0.1μM)	 for	 24,	 48	 and	72h,	 and	 evaluated	 the	 levels	 of	 STAT3	 Tyr705	 phosphorylation.	 We	
Figure	 32.	 Lyn	 assessment	 after	 SHP-1	 inhibition	 by	 Na3VO4.	 A.	 CLL	 B	 cells	 were	 cultivated	with(+)/without(-)	 Na3VO4	 (100μM)	 and	 with	 different	 concentration	 of	 AG490	 (0,	 10,	 50µM).	Immunostainig	 with	 anti-Lyn	 Tyr396,	 anti-Lyn	 and	 anti-β-actin	 antibodies	 highlights	 the	 capability	 of	Na3VO4	 to	 restore	 Lyn	 Tyr396	 phosphorylation	 previously	 inhibits	 by	 AG490	 administration.	 B.	Histograms	 represent	 Lyn	 Tyr396/Lyn	 ratio	 of	western	 blot	 in	 panel	 A.	 Black	 bars:	 CLL	 B	 cells	 alone.	Grey	bars:	B	CLL	cells	+	Na3VO4.	Na3VO4:	sodium	orthovanadate.	
A	
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demonstrated	that	not	only	Lyn	Tyr396,	as	expected,	decreased,	but	STAT3	Tyr705	phosphorylation	was	also	reduced	(Figure	33).		
	All	these	data	suggest	a	link	between	JAK2/STAT3	and	BCR/Lyn	axes.	In	fact,	JAK2	may	be	responsible	for	Lyn	phosphorylation	in	Tyr396	via	SHP-1	protein	and	Lyn	could	be	involved	in	STAT3	activation.		
 	
Figure	 33.	 Assessment	 of	 STAT3	Tyr705	 phosphorylation	 after	Dasatinib	 treatment.	CLL	 B	 cells	were	 cultivated	 for	 24,	48,	 72h	with(+)/without(-)	 Dasatinib	 (0.1µM).	 Dasatinib	 is	 able	 to	 inhibit	both	Lyn	Tyr396	and	STAT3	Tyr	705	phosphorylation.	
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DISCUSSION		The	 in	vivo	CLL	cell	resistance	to	apoptosis	rapidly	decreases	 in	vitro,	marking	 its	 dependence	 on	 the	 extrinsic	 signals	 coming	 from	 the	surrounding	 environment.	 Herein,	 by	 characterizing	 the	 activation	 of	JAK2/STAT3	pathway	 in	 this	 disease	 and	 investigating	 its	 stimulation	 from	tumor	microenvironment,	we	demonstrated	 the	 involvement	 of	 this	 axis	 in	CLL	cell	survival.	We	showed	that	STAT3	is	constitutively	active	in	CLL	cells	and	the	block	of	JAK2/STAT3	pathway	through	specific	inhibitors	affects	the	viability	 of	 the	 neoplastic	 clone	 overcoming	 the	 environmental	 protection.	Moreover,	the	inhibition	of	Lyn,	a	Src	kinase	constitutively	activated	in	CLL,	leads	 to	 STAT3	 dephosphorylation,	 highlighting	 a	 cross-talk	 between	JAK2/STAT3	 axis	 and	 the	 signaling	 initiated	 by	 B	 cell	 receptor	 (BCR)/Lyn	cascade.	JAK2/STAT3	 axis	 is	 one	 of	 the	most	 described	 signaling	 pathway	 in	literature.	 Its	 constitutive	 activation	 occurs	 with	 high	 frequency	 in	 several	hematopoietic	 diseases	 and	 solid	 tumors.	 STAT3	 plays	 a	 critical	 role	 in	pancreatic	tumorigenesis85	and	it	is	an	important	therapeutic	target	in	head	and	 neck	 cancer86.	 Moreover,	 JAK2/STAT3	 pathway	 is	 involved	 in	 the	development	 of	 large	 granular	 lymphocytic	 leukemia87	 and	 acute	 myeloid	leukemia88.			 We	demonstrated	that	STAT3	is	over-expressed	 in	CLL	B	cells	with	 respect	 to	 normal	 B	 lymphocytes.	 We	 analysed	 the	 two	 forms	 of	phosphorylated	 STAT3	 (Ser727	 and	 Tyr705),	 confirming	 the	 constitutive	phosphorylation	 at	 Ser72772,73.	 Noteworthy,	 we	 found	 a	 constitutive	phosphorylation	 of	 STAT3	 in	 Tyr705,	 so	 far	 described	 only	 after	 CLL	 cell	stimulation	with	anti-IgM	or	IL-689.	Actually,	 the	presence	of	STAT3	Tyr705	phosphorylation	in	CLL	remains	controversial,	with	few	studies	that	show	an	inducible	 and	 transient	 STAT3	 Ty3705	 phosphorylation90,	 depending	 on	interleukin-6	(IL-6)73,	a	STAT3	activator91.	Indeed,	the	constitutive	activation	of	STAT3	we	observed	in	CLL	cells	is	probably	due	to	signals	coming	from	the	microenvironment,	 especially	 to	 the	 high	 levels	 of	 IL-6	 released	 from	 the	
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neighbouring	 cells.	 In	 fact,	 our	 results	 also	 showed	 that	 STAT3	 Tyr705	phosphorylation	 is	 further	 up-regulated	 when	 CLL	 cells	 were	 co-cultured	with	 MSCs,	 thus	 supporting	 the	 key	 role	 of	 the	 tumor	 environment	 in	 the	activation	 of	 JAK2/STAT3	 pathway.	 Concerning	 this,	 Levidou	 et	 al.	demonstrated	that	STAT3	is	constitutively	phosphorylated	at	Tyr705	in	CLL	cells	residing	in	the	lymph	node92.		We	 showed	 the	 presence	 of	 phosphorylated	 STAT3	Ty3705	 into	 the	nucleus	 of	 CLL	 cells,	 where	 this	 protein	 can	 exert	 its	 function	 of	transcriptional	 factor	through	the	activation	of	several	pro-survival	genes93.	For	instance,	STAT3	plays	a	key	role	in	supporting	cell	survival	by	promoting	the	 expression	 of	 anti-apoptotic	 factors	 such	 as	 Mcl-1	 and	 Bcl-294–96,	 both	over-expressed	in	CLL,	stressing	the	role	of	STAT3	in	CLL	cell	maintenance.	However,	 the	 meaning	 of	 STAT3	 phosphorylations	 in	 CLL	 is	 still	matter	 of	 debate,	 including	 the	 hypothesis	 that	 STAT3	 Tyr705	phosphorylation	precedes	STAT3	Ser727	phosphorylation97.	Accordingly,	we	found	 an	 effective	 positive	 correlation	 between	 STAT3	 Ser727	 and	 STAT3	Tyr705	phosphorylation	in	CLL	cells.	STAT3	phosphorylation	is	mediated	by	the	tyrosine	kinase	JAK2,	whose	inhibition	leads	to	STAT3	inactivation.		The	kinase	inhibitor	AG490	is	able	to	selectively	block	JAK2	activity	and	to	 induce	 apoptosis	 of	 myeloma	 tumor	 cells	 inoculated	 in	 the	immunodeficient	murine	model	SCID98.	Moreover,	AG490	completely	blocks	the	 growth	 of	 acute	 lymphoblastic	 leukemia	 cells99.	 Our	 experiments	demonstrated	 that	 the	 treatment	 of	 CLL	 B	 cells	 with	 AG490	 inhibits	 JAK2	activation	 preventing	 STAT3	 phosphorylation	 and	 consequently	 affecting	leukemic	cells	viability.	We	 also	 inhibit	 the	 pathway	 downstream	 JAK2	 through	 Stattic,	 that	selectively	inhibits	the	binding	of	STAT3	homodimers	to	DNA	and	increases	the	apoptotic	 rate	of	 STAT3-dependent	breast	 cancer	 cell	 lines82.	Again,	we	observed	 a	 significant	 decrease	 in	 CLL	 cell	 viability.	 The	 same	 experiments	with	AG490	and	Stattic	were	performed	on	leukemic	B	cells	co-cultured	with	MSCs.	We	demonstrated	that	these	inhibitors	are	able	to	induce	apoptosis	in	
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CLL	 B	 cells	 reverting	 the	 resistance	 to	 cytotoxic	 agents	 induced	 by	 the	environment,	bypassing	the	provided	pro-survival	stimuli.	Nowadays,	 therapeutic	 approaches	 aimed	 at	 stopping	 the	 cross-talk	between	tumor	cells	and	the	microenvironment	are	often	used	in	the	clinical	practice.	Lenalidomide	inhibits	the	signals	triggered	by	several	cytokines	(e.g.	TNFalpha,	 VEGF,	 and	 IL-6)	 produced	 by	 the	 cells	 resident	 in	 the	hematopoietic	niche100;	CXCR4	antagonists	inhibit	the	anti-apoptotic	effect	of	CXCL12	 and	 allow	 the	 leukemic	 cell	 egress	 from	 lymph	 node,	 a	 protective	microenvironment,	 to	 the	 circulation101;	 the	 specific	 JAK3	 inhibitor,	 PF-956980,	bypasses	the	cytotoxic	agent	resistance	induced	by	the	treatment	of	CLL	 cells	with	 IL-4102.	Our	data	 and	 these	 results	 suggest	 that	 JAK2/STAT3	inhibitors	 deserve	 further	 investigation	 for	 their	 use	 in	 CLL	 therapy.	 The	knowledge	 of	 the	 relationships	 between	 leukemic	 cells	 and	 the	microenvironment	 will	 allow	 the	 identification	 of	 new	 therapeutic	approaches	 to	 induce	 neoplastic	 cells	 apoptosis,	 thereby	 improving	 the	patient	response.	Following	 BCR	 engagement,	 STAT3	 is	 also	 phosphorylated	 at	 Tyr705	
via	Lyn	and	independently	from	JAK275,77.	With	its	activity,	Lyn	can	mediated	the	phosphorylation	cascade	triggered	by	BCR	engagement	and	culminating	in	the	expression	of	several	genes	 involved	in	cell	growth	and	proliferation.	In	 the	past	years,	we	demonstrated	a	direct	 correlation	between	high	basal	Lyn	activity	and	defects	in	the	induction	of	apoptosis	in	CLL	B	cells48.	We	 observed	 that	 AG490	 treatment	 of	 leukemic	 B	 cells	 inhibited	 the	phosphorylation	of	both	Lyn	at	Tyr396,	inactivating	Lyn	kinase,	and	SHP-1	at	Ser591,	 activating	 SHP-1	 phosphatase.	 Lyn	 and	 SHP-1	 are	 involved	 in	 the	prolonged	 lifespan	 of	 CLL	 B	 cells103.	 SHP-1	 activity	 is	 turned	 on	 by	 JAK2	inhibition.	Adding	sodium	orthovanadate	 (Na3VO4,	 a	phosphatase	 inhibitor)	to	AG490	pre-treated	cells,	we	restored	Lyn	phosphorylation	at	its	active	site	(Tyr396).	 On	 the	 contrary,	 the	 treatment	 of	 CLL	 cells	 with	 Stattic	 did	 not	induce	 any	 change	 in	 SHP-1	 status	 with	 respect	 to	 untreated	 cells	 since	Stattic	 works	 on	 STAT3,	 that	 is	 a	 downstream	 protein	 compared	 to	 JAK2.	Since	 Stattic	 did	 not	 affect	 SHP-1	 activation,	 it	 does	 not	 impact	 on	 Lyn	activation/phosphorylation.	
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The	link	between	JAK2	and	SHP-1	is	still	unclear,	but	a	recent	study	on	chronic	myeloid	leukemia	(CML)	cells	showed	that	Lyn	inhibition	by	AG490	is	mediated	by	SET-PP2A-SHP-1	pathway83.	Moreover,	 a	Lyn	activation	due	to	 a	 strengthening	 SET-mediated	 inhibition	 of	 PP2A	 sustains	 oncogenic	signaling	 in	 CLL104.	 Accordingly,	we	 hypothesize	 that	 even	 in	 CLL,	 SET	 and	PP2A	may	play	 a	 key	 role	 in	 connecting	 the	 cytokine	 receptors	pathway	 to	BCR/Lyn	axis.	However,	this	hypothesis	needs	to	be	further	investigated.	The	 Lyn	 over-expression	 and	 constitutive	 activation	 in	 CLL	 B	 cells	would	 account	 for	 the	 constitutive	 phosphorylation	 of	 STAT3	 at	 Tyr705	observed	 even	 when	 leukemic	 cells	 are	 not	 exposed	 to	 the	microenvironment77.	 As	 a	 further	 support,	 our	 data	 demonstrated	 that	 Lyn	inhibition	by	Dasatinib	produces	STAT3	inactivation.	Summarizing,	 we	 hypothesize	 that	 the	 constitutive	 activation	 of	JAK2/STAT3	 pathway	 in	 CLL	 cells	 leads	 to	 SET	 protein	 activation.	 Once	activated,	 SET	 inhibits	 PP2A	 which,	 in	 turn,	 is	 unable	 to	 activate,	 via	dephosphorylation	 of	 Ser591	 residue,	 SHP-1.	 An	 inactive	 SHP-1	 implies	 a	phosphorylated/active	Lyn	that	may	sustain	STAT3	phosphorylation	(Figure	34).		 						
Bypassing	 the	 pro-survival	 stimuli	 provided	 by	 the	 tumor	microenvironment,	 the	 ability	 of	 AG490	 and	 Stattic	 to	 induce	 apoptosis	 in	leukemic	 B	 cells	 offers	 a	 starting	 point	 for	 the	 development	 of	 new	therapeutic	 strategies	 in	CLL.	This	 study	also	provides	new	 insights	 for	 the	investigation	of	the	pathogenesis	of	CLL	that	focus	the	attention	on	the	cross-talk	between	JAK/STAT	and	BCR/Lyn	axes.		
Figure	34.	 JAK2/STAT3	–	BCR/Lyn	Crosstalk.	A	schematic	 representation	of	 the	molecules	 involved	 in	the	crosstalk.	Normally	in	CLL	B	cells,	JAK2	phosphorylation	leads	to	SET	activation,	therefore	PP2A	is	not	activated	and	SHP-1	is	not	able	to	dephosphorylate/deactivate	Lyn	kinase.	Both	JAK2	and	Lyn	can	activate	STAT3.	Green:	active;	Red:inactive.	
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